

## Author Index for 1992

Åsberg, M. 43:161  
Adinoff, B. 41:89  
Adler, L. 44:21  
Allen, E.M. 42:221  
Alphs, L. 43:87  
Altman, E.S. 41:1  
Altshuler, L. 44:79  
Amin, F. 43:1  
Anderson, D.L. 43:121  
Antonozzi, I. 42:159  
Apter, S. 43:1, 44:153  
Arató, M. 42:189  
Arbisi, P.A. 43:147  
Armitage, R. 41:65  
Asnis, G.M. 43:65, 44:237  
Axelson, D.A. 44:63  
Babron, M.C. 44:171  
Bagby, R.M. 42:73  
Baker, G.B. 41:267, 43:277  
Baker, N. 44:21  
Baker, R. 43:299  
Balldin, J. 41:257  
Balon, R. 43:253  
Banki, C.M. 43:13  
Barnas, C. 42:121  
Battaglia, M. 41:283  
Baxter, L.R., Jr. 42:221  
Beattie, C.W. 43:55  
Bechter, K. 42:193, 42:291  
Beck, A.T. 42:93  
Beck, N.C. 43:231  
Beglin, S.J. 44:191  
Beiser, M. 43:215  
Bela, A. 42:189  
Bellodi, L. 41:283, 42:111  
Berggren, U. 41:257  
Berlanga, C. 44:257  
Berman, S. 42:81  
Bernstein, D. 43:199  
Betz, F. 42:93  
Bielski, R.J. 43:167  
Bienenfeld, D. 41:73  
Bierer, L.M. 42:101  
Bihari, K. 42:267  
Binkert, M. 42:209  
Bissette, G. 43:13  
Böning, J. 41:227  
Boekamp, J. 43:87  
Born, J. 44:125  
Bornstein, R.A. 41:267, 43:277  
Boutros, N.N. 41:249  
Bovier, P. 43:243  
Bowers, M.B., Jr. 41:147  
Boyko, O.B. 44:63  
Bracha, H.S. 43:187  
Brar, J.S. 44:113  
Bridger, W.H. 42:65, 43:263  
Brown, G.M. 43:31, 43:177  
Brown, W.A. 41:203, 44:9  
Buchanan, A. 43:55  
Burgess, J.W. 42:283  
Buysse, D.J. 42:13, 42:27  
Buysse, D.S. 43:43  
Caccavari, R. 41:179  
Calhoun, J.S. 41:65  
Campion, D. 41:99, 41:107, 44:171  
Capesciotti, G. 42:159  
Carter, C.S. 41:137  
Casanova, M.F. 44:79  
Caspari, A. 41:227  
Cassano, G.B. 42:41  
Catapano, F. 44:217  
Cavelier, B. 41:99  
Chaney, J.M. 43:231  
Chapman, H.A. 44:203  
Chauchat, J.-H. 44:55  
Chen, M.-G. 41:203  
Chengappa, K.N.R. 44:113  
Chiodera, P. 41:179  
Christian, J.C. 43:299  
Clay, D.L. 43:231  
Clerget-Darpoux, F. 41:99, 44:171  
Coccaro, E.F. 43:199  
Cohen, R. 41:275  
Coiro, V. 41:179  
Colbert, K. 43:287  
Condello, V. 43:199  
Cooper, T.B. 42:185, 43:137, 43:263  
Copolov, D.L. 41:17  
Corkin, S. 44:167  
Coursey, R.D. 41:115  
Csernansky, J.G. 41:191, 42:81  
Cummings, M.A. 43:121  
Czobor, P. 42:129  
d'Amato, T. 41:99, 41:107, 44:55, 44:171  
Dahl, R.E. 41:53  
Dalery, J. 44:55  
Darko, D.F. 43:111  
Dastoli, C. 42:159  
Davidson, M. 41:155, 42:101, 43:1, 44:153  
Davis, B.M. 41:155  
Davis, J.M. 44:1  
Davis, K.L. 41:155, 42:101, 44:153  
Deakin, J.F.W. 42:273  
Dean, B. 41:17  
DeCaria, C.M. 42:185  
Del Medico, V.J. 44:33  
Delsignore, R. 41:179  
Depue, R.A. 43:147  
des Lauriers, A. 41:107  
Diaferia, G. 42:111  
Dierks, T. 41:227, 44:93  
Dilsaver, S.C. 44:33  
Doraiswamy, P.M. 44:63  
Drebing, C. 44:21  
Drescher, J.P. 44:251  
DuMont, K. 43:1  
Dysken, M.W. 41:37  
Egan, M.F. 43:187  
Ehlers, C.L. 42:13  
El-Mallakh, R.S. 43:187  
Ellinwood, E.H., Jr. 44:63  
Elliott, T.R. 43:231  
Eneroth, P. 43:161  
Erwin, R.J. 42:231, 42:241, 42:253  
Escalona, P.R. 44:63  
Evans, D.L. 44:227  
Faedda, G.L. 41:215  
Fairburn, C.G. 44:191  
Feingold, J. 41:107  
Ferri, E. 42:159  
Filip, V. 41:9  
Filteau, M.-J. 41:107  
Fleischhacker, W.W. 42:121  
Frajese, G. 42:159  
Frank, E. 42:13, 42:27  
Frank, R.G. 43:231  
Frecska, E. 42:189  
Freedman, R. 44:21  
Friedman, L. 41:25  
Friesen, H.G. 41:249  
Frölich, L. 44:93  
Fuchs, D. 42:121  
Fuschino, A. 44:217

Gabriel, S. 41:155, 43:1  
 Gaggiotti, M.T. 41:179  
 Gaillard, J.-M. 43:243  
 Ganguli, R. 44:113  
 Garcia-Borreguero, D. 44:41  
 Garvey, M.J. 42:295  
 Geider, F.J. 42:209  
 Gerhardt, G. 44:21  
 Gerra, G. 41:179  
 Gilbertson, M.W. 42:53  
 Giles, D.E. 41:53  
 Gillin, J.C. 43:111  
 Gillon, D. 43:137  
 Gilmore, G.C. 44:203  
 Goldstein, M.J. 41:1  
 Goodwin, D.C. 41:215  
 Gorwood, P. 41:99, 44:171  
 Goswami, U. 42:189  
 Grambling, S. 43:231  
 Green, M.F. 43:223  
 Greil, W. 4:71  
 Griffin, M. 41:249  
 Growdon, J.H. 44:167  
 Grünberger, J. 41:163  
 Guilloud-Bataille, M. 41:107  
 Gur, R.C. 42:231, 42:241, 42:253  
 Gur, R.E. 42:231, 42:241, 42:253  
 Gurklis, J.A. 42:53  
 Guze, B.H. 42:221  
 Hálková, E. 41:9  
 Halle, L. 41:99  
 Halper, J.P. 42:1  
 Hamilton, S. 41:73  
 Harvey, P. 43:199, 44:141, 44:153  
 Haviland, M.G. 43:121  
 Hegerl, U. 44:181  
 Heimberg, C. 42:241, 42:253  
 Heinrich, H. 44:125  
 Heninger, G.R. 43:77  
 Herzog, S. 42:193, 42:291  
 Hewlett, W.A. 42:81  
 Hill, C. 41:17  
 Hill, J.L. 42:267  
 Hillaire, D. 41:99, 41:107, 44:171  
 Hinterhuber, H. 42:121  
 Hirschowitz, J. 41:155  
 Hoch, C.C. 43:43  
 Hollander, E. 42:41, 42:185  
 Holsboer, F. 44:41  
 Horvath, T.B. 43:199  
 Houck, P. 43:23, 41:237  
 Hubbard, R.W. 43:121  
 Huff, F.J. 44:167  
 Husted, J.A. 43:215  
 Hwang, S. 41:1  
 Iacono, W.G. 43:215  
 Ihl, R. 44:93  
 Irwin, M.R. 43:111  
 Jaeckle, R. 41:45  
 Janicak, P.G. 44:1  
 Jarrett, D.B. 43:23  
 Jatlow, P.I. 41:147  
 Jauss, M. 42:209  
 Jay, M. 41:99, 41:107, 44:171  
 Jesberger, J.A. 41:25  
 Joffe, R.T. 42:73  
 Johnson, M.F. 41:203  
 Joseph, K.C. 43:299  
 Kahn, R.S. 41:155, 43:1, 43:65  
 Kaplan, C. 41:99  
 Karege, F. 43:243  
 Karen, P. 41:9  
 Karmacs, L. 43:13  
 Kathol, R.G. 41:45  
 Kay, D.R. 43:231  
 Kay, S.R. 42:199  
 Keefe, R.S.E. 44:141, 44:153  
 Keitner, G.I. 44:9  
 Kelley, M.P. 41:115  
 Kellner, R. 42:171  
 Kemali, D. 44:217  
 Kemmler, G. 42:121  
 Kennedy, S.H. 43:177  
 Kern, R.S. 43:223  
 Keshavan, M.S. 43:23  
 Kim, S.W. 41:37  
 Kindler, S. 43:137  
 Kleber, H.D. 43:77  
 Kleinman, J.E. 44:79  
 Knott, P. 43:199  
 Körber, J. 41:227  
 Kohn, R. 44:9  
 Kojima, T. 43:129  
 Koponen, H.J. 44:107  
 Korenovsky, A. 43:23  
 Kornhuber, H.H. 44:125  
 Koshino, Y. 43:129  
 Kosten, T.R. 43:77  
 Kraemer, H.C. 42:241  
 Krauss, S.S. 43:147  
 Krieg, J.-C. 44:41  
 Krishnan, K.R.R. 44:63  
 Kulkarni, J. 41:17  
 Kupfer, D.J. 41:53, 42:13, 42:27, 43:43  
 Kuskowski, M. 41:37  
 Laklou, H. 44:171  
 Lam, R.W. 43:55  
 Lauer, C.J. 44:41  
 Laurent, A. 44:55  
 Lawrence, E.K. 43:199  
 Lawrence, T.L. 43:199  
 Leboyer, M. 41:99, 41:107, 44:171  
 Lensi, P. 42:41  
 Lenzenweger, M.F. 44:141, 44:153  
 Lerer, B. 43:137  
 Levitt, A.J. 42:73  
 Lichtenberg, P. 43:137  
 Liebowitz, M.R. 42:185  
 Lindenmayer, J.-P. 42:199  
 Lindstedt, G. 41:257  
 Lindström, E.M. 42:145  
 Lindström, L.H. 42:146  
 Linnoila, M. 41:89  
 Linzmayer, L. 41:163  
 Liukkonen, J. 44:107  
 Lohr, J.B. 43:187  
 Loimer, N. 41:163  
 Lucca, A. 44:85  
 Lucini, V. 44:85  
 Lycaki, H. 43:253  
 Machen, M. 43:43  
 MacMurray, J.P. 43:121  
 Mador, J.A. 43:55  
 Maes, M. 42:295  
 Magnani, A. 42:159  
 Mahadik, S.P. 43:23  
 Mahon, T. 43:199  
 Maj, M. 44:217  
 Malafosse, A. 44:171  
 Mallet, J. 44:171  
 Malmgren, R. 43:161  
 Malone, V. 41:17  
 Mancini, C. 43:31  
 Maninetti, L. 41:179  
 Marazziti, D. 42:41  
 Marie-Cardine, M. 44:55  
 Maršálek, M. 41:9  
 Martin, E.-M. 44:93  
 Martin, K. 42:81  
 Mather, J.A. 43:93  
 Maurer, K. 44:93  
 Mawhinney-Hee, M. 42:231  
 Mayerhofer, S. 41:163  
 Mayor, J. 43:167  
 Mazumdar, S. 41:237  
 Mazure, C.M. 41:147

McBride, R. 43:253  
 McDonald, W.M. 44:63  
 McDougle, C.J. 43:77  
 McGhee, W.H. 43:121  
 Mefford, I. 41:89  
 Meltzer, H.Y. 41:25, 42:159  
 Merskey, H. 43:93  
 Miklowitz, D.J. 41:1  
 Miller, I.W. 44:9  
 Miller, M.D. 41:237  
 Mintz, J. 41:1  
 Miyasaka, M. 43:129  
 Modai, I. 43:161  
 Modestin, J. 44:251  
 Modigh, K. 41:257  
 Mohs, R.C. 42:101, 44:141,  
     44:153, 44:168  
 Monk, T.H. 42:13, 42:27  
 Montani, G. 41:179  
 Monteleone, P. 44:217  
 Moore, C. 41: 155  
 Mouton, A. 42:53  
 Müller-Oerlinghausen, B.  
     44:181  
 Muller, B. 41:99  
 Mulsant, B. 41:237  
 Murkejee, S. 43:23  
 Murphy, D.L. 42:267  
 Nakane, Y. 43:129  
 Nelson, J.C. 41:147, 43:121  
 Nelson, S. 41:73  
 Nemerooff, C.B. 43:13, 44:63  
 Nerozzi, D. 42:159  
 Neufeld, R.W.J. 43:93  
 Newcomer, J.W. 41:191  
 Newman, M.E. 43:137  
 Neylan, T.C. 42:53  
 Niedermeier, T. 41:275  
 Nordahl, T.E. 41:137  
 Norman, W.H. 44:9  
 Nousiainen, U. 44:107  
 Nurnberger, J.I., Jr. 43:299  
 Öhlund, L.S. 42:145  
 Öhman, A. 42:145  
 Özdaglar, A. 44:41  
 O'Connor, D.T. 42:53  
 Ontiveros, M. 44:257  
 Ortega-Soto, H.A. 44:257  
 Osterheimer, M. 41:227  
 Pakesch, G. 41:163  
 Palumbo, D.R. 42:1  
 Palumbo, J.M. 43:77  
 Pandey, G.N. 44:1  
 Paradis, C.F. 41:237  
 Pasatiempo, A.P. 42:65,  
     43:263  
 Pasternak, R.E. 43:43  
 Pathak, D. 42:171  
 Patterson, L.J. 44:63  
 Peabody, C.A. 41:249  
 Perenyi, A. 42:189  
 Peters, J.L. 42:53, 43:287  
 Petitto, J.M. 44:227  
 Pfersmann, D. 41:163  
 Piatti, E. 44:85  
 Plutchik, R. 42:199  
 Pogge, D.L. 44:141  
 Pohl, R. 43:253  
 Price, L.H. 43:77  
 Qamar, A.B. 44:33  
 Quade, D. 44:227  
 Rabin, B.S. 44:113  
 Rabinovich, H. 42:65, 43:263  
 Ramaswamy, G. 41:73  
 Ravagli, S. 42:41  
 Rea, M.M. 41:1  
 Reitz, C. 42:209  
 Reynolds, C.F., III 41:237,  
     43:23, 43:43  
 Rice, J. 43:167  
 Rifai, A.H. 41:237  
 Riney, S.J. 41:191  
 Risch, S.C. 43:111  
 Ritchie, J.C. 44:63  
 Ritenour, A. 42:13, 42:27  
 Robertson, L.C. 41:137  
 Rochet, T. 44:55  
 Roffwarg, H.P. 41:53, 41:65  
 Ronchi, P. 42:111, 44:85  
 Royston, M.C. 42:273  
 Rush, A.J. 41:65  
 Russell, N.C. 43:93  
 Ryan, C.E. 44:9  
 Sabate, O. 44:171  
 Sanderson, W.C. 42:93, 43:65,  
     44:237  
 Saoud, J.B. 42:185  
 Satz, P. 43:223  
 Sauer, H. 42:209  
 Schlernitzauer, M. 43:43  
 Schmeidler, J. 42:101, 44:153  
 Schreiber, H. 44:125  
 Schröder, J. 42:209  
 Schüttler, R. 42:193, 42:291  
 Sciuto, G. 42:111  
 Senties, H. 44:257  
 Serper, M.R. 44:141  
 Shapira, B. 43:137  
 Sharma, R.P. 44:1  
 Shear, M.K. 42:1  
 Sherman, B.M. 41:45  
 Shimazono, Y. 43:129  
 Shrikanthan, P. 41:17  
 Shtasel, D.L. 42:253  
 Shutty, M.S. 43:231  
 Siever, L.J. 43:1, 43:199  
 Silverman, J.M. 42:101  
 Simpson, M.D.C. 42:273  
 Sinha, D. 41:73  
 Sitaram, N. 43:299  
 Skolnick, B. 42:231  
 Slater, P. 42:273  
 Smailis, J. 42:231  
 Smeraldi, E. 42:111, 44:85  
 Solomon, W. 44:113  
 Soufflet, M.F. 41:99  
 Sperner-Unterweger, B. 42:121  
 Spoont, M. 43:147  
 Stack, J.A. 41:237  
 Stanley, M. 42:185  
 Starcevic, V. 42:171  
 Stein, D.J. 42:185  
 Steinhauer, S.R. 43:287  
 Steller, B. 44:71  
 Stern, R.G. 41:155, 42:101,  
     43:1, 44:168  
 Stoff, D.M. 42:65, 43:263  
 Stoll, A.L. 41:215  
 Stoltz-Born, G. 44:125  
 Strakowski, S.M. 41:215  
 Strauss, M.E. 43:87, 44:203  
 Strik, W.K. 41:227  
 Suddath, R.L. 43:187  
 Sweeney, J.A. 42:1  
 Szuba, M.P. 42:221  
 Takahashi, R. 43:129  
 Terra, J.-L. 44:55  
 Thienhaus, O. 41:73  
 Tissot, R. 43:243  
 Toffler, G. 44:251  
 Tohen, M. 41:215  
 Trestman, R.L. 43:199  
 Trungold, S. 42:185  
 Uhlenhuth, E.H. 42:171  
 Valevski, A. 43:161  
 van Kammen, D.P. 42:53,  
     43:287  
 van Praag, H.M. 43:65, 44:237  
 Vinogradov, S. 41:191, 42:81  
 Volavka, J. 42:129  
 Volpi, R. 41:179  
 Wachter, H. 42:121

Waksman, G. 44:171  
Waldo, M. 44:21  
Warner, M.D. 41:249  
Watzl, H. 41:275  
Waxman, R. 41:89  
Weinberger, D.R. 44:79  
Weiss, K.M. 44:203  
Wetterberg, L. 43:161  
Wetzler, S. 42:93, 43:65

Widlöcher, D. 41:107  
Widmer, J. 43:243  
Worsley, I.G. 41:249  
Wulff, H. 44:181  
Wyatt, R.J. 43:187  
Wysham, C. 41:45  
Yager, A. 42:221  
Yagi, G. 43:129

Yamauchi, T. 43:129  
Yang, R.-K. 43:199  
Yeragani, V.K. 43:253  
Yeung, J. 42:65, 43:263  
Zemlan, F.P. 41:73  
Zito, M. 44:79  
Zubin, J. 43:287  
Zwil, A.S. 42:241

## Subject Index for 1992

### **Abnormal movements**

dyskinesia, haloperidol, 41:191  
dyskinesia, homovanillic acid, 41:191  
dyskinesia, negative symptoms, 41:191  
dyskinesia, neuroleptics, 41:191  
dyskinesia, prolactin, 41:191  
dyskinesia, schizophrenia, 41:191  
dyskinesia, side effects, 41:191  
haloperidol, dyskinesia, 41:191  
haloperidol, homovanillic acid, 41:191  
haloperidol, negative symptoms, 41:191  
haloperidol, prolactin, 41:191  
haloperidol, schizophrenia, 41:191  
homovanillic acid, dyskinesia, 41:191  
homovanillic acid, haloperidol, 41:191  
homovanillic acid, negative symptoms, 41:191  
homovanillic acid, neuroleptics, 41:191  
homovanillic acid, prolactin, 41:191  
homovanillic acid, schizophrenia, 41:191  
negative symptoms, dyskinesia, 41:191  
negative symptoms, haloperidol, 41:191  
negative symptoms, homovanillic acid, 41:191  
negative symptoms, neuroleptics, 41:191  
negative symptoms, prolactin, 41:191  
negative symptoms, schizophrenia, 41:191  
neuroleptics, dyskinesia, 41:191  
neuroleptics, homovanillic acid, 41:191  
neuroleptics, negative symptoms, 41:191  
neuroleptics, prolactin, 41:191  
neuroleptics, schizophrenia, 41:191  
prolactin, dyskinesia, 41:191  
prolactin, haloperidol, 41:191  
prolactin, homovanillic acid, 41:191  
prolactin, negative symptoms, 41:191  
prolactin, neuroleptics, 41:191  
prolactin, schizophrenia, 41:191  
prolactin, side effects, 41:191  
schizophrenia, dyskinesia, 41:191  
schizophrenia, haloperidol, 41:191  
schizophrenia, homovanillic acid, 41:191  
schizophrenia, negative symptoms, 41:191  
schizophrenia, neuroleptics, 41:191  
schizophrenia, prolactin, 41:191  
**ACTH (adrenocorticotrophic hormone)**  
adolescents, beta-endorphin, 41:179  
adolescents, exercise, 41:179  
antidepressants, cortisol, 41:45  
antidepressants, glucose, 41:45  
antidepressants, insulin tolerance test, 41:45  
antidepressants, normal subjects, 41:45  
beta-endorphin, adolescents, 41:179

### **ACTH continued**

beta-endorphin, exercise, 41:179  
cortisol, antidepressants, 41:45  
cortisol, glucose, 41:45  
cortisol, imipramine, 41:45  
cortisol, insulin tolerance test, 41:45  
cortisol, normal subjects, 41:45  
exercise, adolescents, 41:179  
exercise, beta-endorphin, 41:179  
glucose, antidepressants, 41:45  
glucose, cortisol, 41:45  
glucose, imipramine, 41:45  
glucose, insulin tolerance test, 41:45  
glucose, normal subjects, 41:45  
imipramine, cortisol, 41:45  
imipramine, glucose, 41:45  
imipramine, insulin tolerance test, 41:45  
imipramine, normal subjects, 41:45  
insulin tolerance test, antidepressants, 41:45  
insulin tolerance test, cortisol, 41:45  
insulin tolerance test, glucose, 41:45  
insulin tolerance test, imipramine, 41:45  
insulin tolerance test, normal subjects, 41:45  
MCPP, prolactin, 43:1  
MCPP, schizophrenia, 43:1  
MCPP, serotonin, 43:1  
MCPP, temperature of body, 43:1  
normal subjects, antidepressants, 41:45  
normal subjects, cortisol, 41:45  
normal subjects, glucose, 41:45  
normal subjects, imipramine, 41:45  
normal subjects, insulin tolerance test, 41:45  
prolactin, MCPP, 43:1  
prolactin, schizophrenia, 43:1  
prolactin, serotonin, 43:1  
prolactin, temperature of body, 43:1  
schizophrenia, MCPP, 43:1  
schizophrenia, prolactin, 43:1  
schizophrenia, serotonin, 43:1  
schizophrenia, temperature of body, 43:1  
serotonin, MCPP, 43:1  
serotonin, prolactin, 43:1  
serotonin, schizophrenia, 43:1  
serotonin, temperature of body, 43:1  
temperature of body, MCPP, 43:1  
temperature of body, prolactin, 43:1  
temperature of body, schizophrenia, 43:1  
temperature of body, serotonin, 43:1  
**Adolescents**  
ACTH, beta-endorphin, 41:179  
ACTH, exercise, 41:179

**Adolescents** continued  
 affective disorder, sleep, 41:53  
 beta-endorphin, ACTH, 41:179  
 beta-endorphin, exercise, 41:179  
 exercise, ACTH, 41:179  
 exercise, beta-endorphin, 41:179  
 sleep, affective disorder, 41:53  
**Adrenergic receptor**  
 affective disorder, blood pressure, 41:257  
 affective disorder, clonidine, 41:257  
 affective disorder, depressive symptoms, 41:257  
 affective disorder, electroconvulsive therapy, 41:257  
 affective disorder, growth hormone, 41:257  
 affective disorder, magnesium, 43:243  
 affective disorder, MHPG, 43:243  
 blood pressure, affective disorder, 41:257  
 blood pressure, clonidine, 41:257  
 blood pressure, depressive symptoms, 41:257  
 blood pressure, electroconvulsive therapy, 41:257  
 blood pressure, growth hormone, 41:257  
 clonidine, affective disorder, 41:257  
 clonidine, blood pressure, 41:257  
 clonidine, depressive symptoms, 41:257  
 clonidine, electroconvulsive therapy, 41:257  
 clonidine, growth hormone, 41:257  
 depressive symptoms, affective disorder, 41:257  
 depressive symptoms, blood pressure, 41:257  
 depressive symptoms, clonidine, 41:257  
 depressive symptoms, electroconvulsive therapy, 41:257  
 depressive symptoms, growth hormone, 41:257  
 electroconvulsive therapy, affective disorder, 41:257  
 electroconvulsive therapy, blood pressure, 41:257  
 electroconvulsive therapy, clonidine, 41:257  
 electroconvulsive therapy, depressive symptoms, 41:257  
 electroconvulsive therapy, growth hormone, 41:257  
 growth hormone, affective disorder, 41:257  
 growth hormone, blood pressure, 41:257  
 growth hormone, clonidine, 41:257  
 growth hormone, depressive symptoms, 41:257  
 growth hormone, electroconvulsive therapy, 41:257  
 magnesium, affective disorder, 43:243  
 magnesium, MHPG, 43:243  
 MHPG, affective disorder, 43:243

**Adrenergic receptor** continued  
 MHPG, magnesium, 43:243  
**Affective disorder**  
 adenosyl-L-methionine, antidepressants, 44:257  
 adenosyl-L-methionine, imipramine, 44:257  
 adinazolam, antidepressants, 43:177  
 adinazolam, desipramine, 43:177  
 adinazolam, melatonin, 43:177  
 adolescent depression, childhood depression, 41:53  
 adolescent depression, family studies, 41:53  
 adolescent depression, polysomnography, 41:53  
 adolescent depression, sleep, 41:53  
 adrenergic receptor, blood pressure, 41:257  
 adrenergic receptor, clonidine, 41:257  
 adrenergic receptor, depressive symptoms, 41:257  
 adrenergic receptor, electroconvulsive therapy, 41:257  
 adrenergic receptor, growth hormone, 41:257  
 adrenergic receptor, magnesium, 43:243  
 adrenergic receptor, MHPG, 43:243  
 age, cortisol, 44:9  
 age, dexamethasone suppression test, 44:9  
 age, sex differences, 44:9  
 agoraphobia, comorbidity, 42:171  
 agoraphobia, generalized anxiety disorder, 42:171  
 agoraphobia, panic disorder, 42:171  
 agoraphobia, panic disorder, 44:41  
 agoraphobia, polysomnography, 44:41  
 agoraphobia, sleep, 44:41  
 amino acids in plasma, obsessive-compulsive disorder, 44:91  
 aminoacids in plasma, tryptophan, 44:91  
 antidepressants, adenosyl-L-methionine, 44:257  
 antidepressants, adinazolam, 43:177  
 antidepressants, clinical features, 41:203  
 antidepressants, melatonin, 43:177  
 antidepressants, placebo, 41:203  
 antidepressants, response, 41:203  
 anxiety, comorbidity, 42:93  
 anxiety, dysthymia, 42:93  
 anxiety, MHPG, 42:295  
 anxiety, personality disorder, 42:93  
 augmenting-reducing, evoked potentials, 44:181  
 augmenting-reducing, lithium, 44:181  
 beta-endorphin, immunology, 43:111  
 beta-endorphin, natural killer cells, 43:111  
 bipolar, prodrome, 41:1  
 bipolar, relapse, 41:1  
 blood pressure, adrenergic receptor, 41:257

**Affective disorder continued**

blood pressure, clonidine, 41:257, 43:199  
 blood pressure, depressive symptoms, 41:257  
 blood pressure, electroconvulsive therapy, 41:257  
 blood pressure, growth hormone, 41:257  
 blood pressure, heart rate, 43:199  
 blood pressure, MHPG, 43:199  
 blood pressure, norepinephrine, 43:199  
 childhood depression, adolescent depression, 41:53  
 childhood depression, family studies, 41:53  
 childhood depression, polysomnography, 41:53  
 childhood depression, sleep, 41:53  
 chronic medical illness burden, elderly, 41:237  
 circadian rhythm, depressed mood, 43:147  
 circadian rhythm, phototherapy, 43:147  
 circadian rhythm, seasonal depression, 43:147  
 circadian rhythms, social activity, 42:221  
 clinical features, antidepressants, 41:203  
 clinical features, placebo, 41:203  
 clinical features, response, 41:203  
 clonidine, adrenergic receptor, 41:257  
 clonidine, blood pressure, 41:257, 43:199  
 clonidine, depressive symptoms, 41:257  
 clonidine, electroconvulsive therapy, 41:257  
 clonidine, growth hormone, 41:257  
 clonidine, heart rate, 43:199  
 clonidine, MHPG, 43:199  
 clonidine, norepinephrine, 43:199  
 comorbidity, agoraphobia, 42:171  
 comorbidity, anxiety, 42:93  
 comorbidity, dysthymia, 42:93  
 comorbidity, generalized anxiety disorder, 42:171  
 comorbidity, genetics, 42:111  
 comorbidity, obsessive-compulsive disorder, 42:111  
 comorbidity, panic disorder, 42:171  
 comorbidity, personality disorder, 42:93  
 comorbidity, social phobia, 44:33  
 comorbidity, treatment response, 44:33  
 cortisol, age, 44:9  
 cortisol, desipramine, 43:65, 44:237  
 cortisol, dexamethasone suppression test, 44:9, 44:63, 44:227  
 cortisol, dopamine, 43:31  
 cortisol, epinephrine in urine, 43:31  
 cortisol, fenfluramine, 43:137  
 cortisol, magnetic resonance imaging, 44:63  
 cortisol, MCPP, 43:65  
 cortisol, melancholia, 43:137  
 cortisol, monoamine oxidase, 44:1  
 cortisol, norepinephrine, 43:65

**Affective disorder continued**

cortisol, norepinephrine in urine, 43:31  
 cortisol, object loss, 44:227  
 cortisol, panic disorder, 43:65  
 cortisol, pituitary volume, 44:63  
 cortisol, prolactin, 43:137  
 cortisol, schizophrenia, 44:1  
 cortisol, serotonin, 43:65, 43:137  
 cortisol, sex differences, 44:9  
 cortisol, suicide, 43:31  
 delta EEG, polysomnography, 41:65  
 delta EEG, sleep, 41:65  
 depressed mood, circadian rhythm, 43:147  
 depressed mood, emotion, 42:241  
 depressed mood, facial affective discrimination, 42:241  
 depressed mood, phototherapy, 43:147  
 depressed mood, seasonal depression, 43:147  
 depressive symptoms, adrenergic receptor, 41:257  
 depressive symptoms, blood pressure, 41:257  
 depressive symptoms, clonidine, 41:257  
 depressive symptoms, electroconvulsive therapy, 41:257  
 depressive symptoms, growth hormone, 41:257  
 desipramine, adinazolam, 43:177  
 desipramine, cortisol, 43:65, 44:237  
 desipramine, MCPP, 43:65  
 desipramine, melatonin, 43:177  
 desipramine, norepinephrine, 43:65  
 desipramine, panic disorder, 43:65  
 desipramine, serotonin, 43:65  
 dexamethasone suppression test, age, 44:9  
 dexamethasone suppression test, cortisol, 44:9, 44:63, 44:237  
 dexamethasone suppression test, magnetic resonance imaging, 44:63  
 dexamethasone suppression test, object loss, 44:227  
 dexamethasone suppression test, pituitary volume, 44:63  
 dexamethasone suppression test, sex differences, 44:9  
 dopamine, cortisol, 43:31  
 dopamine, epinephrine in urine, 43:31  
 dopamine, norepinephrine in urine, 43:31  
 dopamine, suicide, 43:31  
 dysthymia, anxiety, 42:93  
 dysthymia, comorbidity, 42:93  
 dysthymia, personality disorder, 42:93  
 elderly, chronic medical illness burden, 41:237  
 electroconvulsive therapy, adrenergic receptor, 41:257

**Affective disorder** continued

- electroconvulsive therapy, blood pressure, 41:257
- electroconvulsive therapy, clonidine, 41:257
- electroconvulsive therapy, depressive symptoms, 41:257
- electroconvulsive therapy, growth hormone, 41:257
- electroretinography, seasonal depression, 43:55
- emotion, depressed mood, 42:241
- emotion, facial affective discrimination, 42:241
- epinephrine in urine, cortisol, 43:31
- epinephrine in urine, dopamine, 43:31
- epinephrine in urine, norepinephrine in urine, 43:31
- epinephrine in urine, suicide, 43:31
- evoked potentials, augmenting-reducing, 44:181
- evoked potentials, lithium, 44:181
- eye movements, paranoid subtype, 43:93
- eye movements, saccades, 43:93
- eye movements, schizophrenia, 43:93
- facial affective discrimination, depressed mood, 42:241
- facial affective discrimination, emotion, 42:241
- family studies, adolescent depression, 41:53
- family studies, childhood depression, 41:53
- family studies, polysomnography, 41:53
- family studies, sleep, 41:53
- fenfluramine, cortisol, 43:137
- fenfluramine, melancholia, 43:137
- fenfluramine, prolactin, 43:137
- fenfluramine, serotonin, 43:137
- generalized anxiety disorder, agoraphobia, 42:171
- generalized anxiety disorder, comorbidity, 42:171
- generalized anxiety disorder, panic disorder, 42:171
- genetics, comorbidity, 42:111
- genetics, obsessive-compulsive disorder, 42:111
- growth hormone, adrenergic receptor, 41:257
- growth hormone, blood pressure, 41:257
- growth hormone, clonidine, 41:257
- growth hormone, depressive symptoms, 41:257
- growth hormone, electroconvulsive therapy, 41:257
- heart rate, blood pressure, 43:199
- heart rate, clonidine, 43:199
- heart rate, MHPG, 43:199
- heart rate, norepinephrine, 43:199
- imipramine, adenosyl-L-methionine, 44:257
- imipramine, antidepressants, 44:257
- immunology, beta-endorphin, 43:111
- Affective disorder** continued
- immunology, natural killer cells, 43:111
- ionselective electrode, lithium, 44:71
- ionselective electrode, whole blood measurement, 44:71
- light spectral value, phototherapy, 43:167
- light spectral value, seasonal depression, 43:167
- lithium, augmenting-reducing, 44:181
- lithium, evoked potentials, 44:181
- lithium, ion selective electrode, 44:71
- lithium, whole blood measurement, 44:71
- longitudinal studies, polysomnography, 42:27
- longitudinal studies, psychotherapy, 42:27
- longitudinal studies, remission, 42:27
- longitudinal studies, sleep, 42:27
- magnesium, adrenergic receptor, 43:243
- magnesium, MHPG, 43:243
- magnetic resonance imaging, cortisol, 44:63
- magnetic resonance imaging, dexamethasone suppression test, 44:63
- magnetic resonance imaging, pituitary volume, 44:63
- manic psychosis, perphenazine, 41:147
- manic psychosis, psychotic depression, 41:147
- manic psychosis, symptom response, 41:147
- manic symptoms, psychotic symptoms, 41:215
- manic symptoms, Tridimensional Personality Questionnaire, 41:215
- MCPP, cortisol, 43:65
- MCPP, desipramine, 43:65
- MCPP, norepinephrine, 43:65
- MCPP, panic disorder, 43:65
- MCPP, serotonin, 43:65
- melancholia, cortisol, 43:137
- melancholia, fenfluramine, 43:137
- melancholia, prolactin, 43:137
- melancholia, serotonin, 43:137
- melancholia, thyrotropin, 42:73
- melancholia, thyroxine, 42:73
- melancholia, triiodothyronine, 42:73
- melatonin, adinazolam, 43:177
- melatonin, antidepressants, 43:177
- melatonin, desipramine, 43:177
- MHPG, adrenergic receptor, 43:243
- MHPG, anxiety, 42:295
- MHPG, blood pressure, 43:199
- MHPG, clonidine, 43:199
- MHPG, heart rate, 43:199
- MHPG, magnesium, 43:243
- MHPG, norepinephrine, 43:199
- monoamine oxidase, cortisol, 44:1
- monoamine oxidase, schizophrenia, 44:1
- natural killer cells, beta-endorphin, 43:111

**Affective disorder** continued

natural killer cells, immunology, 43:111  
 norepinephrine, blood pressure, 43:199  
 norepinephrine, clonidine, 43:199  
 norepinephrine, cortisol, 43:65  
 norepinephrine, desipramine, 43:65  
 norepinephrine, heart rate, 43:199  
 norepinephrine in urine, cortisol, 43:31  
 norepinephrine in urine, dopamine, 43:31  
 norepinephrine in urine, epinephrine in urine, 43:31  
 norepinephrine in urine, suicide, 43:31  
 norepinephrine, MCPP, 43:65  
 norepinephrine, MHPG, 43:199  
 norepinephrine, panic disorder, 43:65  
 norepinephrine, serotonin, 43:65  
 object loss, cortisol, 44:227  
 object loss, dexamethasone suppression test, 44:227  
 obsessive-compulsive disorder, amino acids in plasma, 44:91  
 obsessive-compulsive disorder, comorbidity, 42:111  
 obsessive-compulsive disorder, genetics, 42:111  
 obsessive-compulsive disorder, tryptophan, 44:91  
 panic disorder, agoraphobia, 42:171, 44:41  
 panic disorder, comorbidity, 42:171  
 panic disorder, cortisol, 43:65  
 panic disorder, desipramine, 43:65  
 panic disorder, generalized anxiety disorder, 42:171  
 panic disorder, MCPP, 43:65  
 panic disorder, norepinephrine, 43:65  
 panic disorder, polysomnography, 44:41  
 panic disorder, serotonin, 43:65  
 panic disorder, sleep, 44:41  
 paranoid subtype, eye movements, 43:93  
 paranoid subtype, saccades, 43:93  
 paranoid subtype, schizophrenia, 43:93  
 perphenazine, manic psychosis, 41:147  
 perphenazine, psychotic depression, 41:147  
 perphenazine, symptom response, 41:147  
 personality disorder, anxiety, 42:93  
 personality disorder, comorbidity, 42:93  
 personality disorder, dysthymia, 42:93  
 phototherapy, circadian rhythm, 43:147  
 phototherapy, depressed mood, 43:147  
 phototherapy, light spectral value, 43:167  
 phototherapy, seasonal depression, 43:147, 43:167  
 pituitary volume, cortisol, 44:63  
 pituitary volume, dexamethasone suppression test, 44:63

**Affective disorder** continued

pituitary volume, magnetic resonance imaging, 44:63  
 placebo, antidepressants, 41:203  
 placebo, clinical features, 41:203  
 placebo, response, 41:203  
 polysomnography, adolescent depression, 41:53  
 polysomnography, agoraphobia, 44:41  
 polysomnography, childhood depression, 41:53  
 polysomnography, delta EEG, 41:65  
 polysomnography, family studies, 41:53  
 polysomnography, longitudinal studies, 42:27  
 polysomnography, panic disorder, 44:41  
 polysomnography, psychotherapy, 42:13, 42:27  
 polysomnography, remission, 42:27  
 polysomnography, sleep, 41:53, 41:65, 42:13, 42:27, 44:41  
 polysomnography, treatment response, 42:13  
 prodrome, bipolar, 41:1  
 prodrome, relapse, 41:1  
 prolactin, cortisol, 43:137  
 prolactin, fenfluramine, 43:137  
 prolactin, melancholia, 43:137  
 prolactin, serotonin, 43:137  
 psychotherapy, longitudinal studies, 42:27  
 psychotherapy, polysomnography, 42:13, 42:27  
 psychotherapy, remission, 42:27  
 psychotherapy, sleep, 42:13, 42:27  
 psychotherapy, treatment response, 42:13  
 psychotic depression, manic psychosis, 41:147  
 psychotic depression, perphenazine, 41:147  
 psychotic depression, symptom response, 41:147  
 psychotic symptoms, manic symptoms, 41:215  
 psychotic symptoms, Tridimensional Personality Questionnaire, relapse, bipolar, 41:1  
 relapse, prodrome, 41:1  
 remission, longitudinal studies, 42:27  
 remission, polysomnography, 42:27  
 remission, psychotherapy, 42:27  
 remission, sleep, 42:27  
 response, antidepressants, 41:203  
 response, clinical features, 41:203  
 response, placebo, 41:203  
 saccades, eye movements, 43:93  
 saccades, paranoid subtype, 43:93  
 saccades, schizophrenia, 43:93  
 schizophrenia, cortisol, 44:1  
 schizophrenia, eye movements, 43:93  
 schizophrenia, monoamine oxidase, 44:1  
 schizophrenia, paranoid subtype, 43:93  
 schizophrenia, saccades, 43:93

**Affective disorder** continued

- seasonal depression, circadian rhythm, 43:147
- seasonal depression, depressed mood, 43:147
- seasonal depression, electroretinography, 43:55
- seasonal depression, light spectral value, 43:167
- seasonal depression, phototherapy, 43:147, 43:167
- serotonin, cortisol, 43:65, 43:137
- serotonin, desipramine, 43:65
- serotonin, fenfluramine, 43:137
- serotonin, MCPP, 43:65
- serotonin, melancholia, 43:137
- serotonin, norepinephrine, 43:65
- serotonin, panic disorder, 43:65
- serotonin, prolactin, 43:137
- sex differences, age, 44:9
- sex differences, cortisol, 44:9
- sex differences, dexamethasone suppression test, 44:9
- sleep, adolescent depression, 41:53
- sleep, agoraphobia, 44:41
- sleep, childhood depression, 41:53
- sleep, delta EEG, 41:65
- sleep, family studies, 41:53
- sleep, longitudinal studies, 42:27
- sleep, panic disorder, 44:41
- sleep, polysomnography, 41:53, 41:65, 42:13, 42:27, 44:41
- sleep, psychotherapy, 42:13, 42:27
- sleep, remission, 42:27
- sleep, treatment response, 42:13
- socialactivity, circadian rhythms, 42:221
- social phobia, comorbidity, 44:33
- social phobia, treatment response, 44:33
- suicide, cortisol, 43:31
- suicide, dopamine, 43:31
- suicide, epinephrine in urine, 43:31
- suicide, norepinephrine in urine, 43:31
- symptom response, manic psychosis, 41:147
- symptom response, perphenazine, 41:147
- symptom response, psychotic depression, 41:147
- thyrotropin, melancholia, 42:73
- thyrotropin, thyroxine, 42:73
- thyrotropin, triiodothyronine, 42:73
- thyroxine, melancholia, 42:73
- thyroxine, thyrotropin, 42:73
- thyroxine, triiodothyronine, 42:73
- treatment response, comorbidity, 44:33
- treatment response, polysomnography, 42:13
- treatment response, psychotherapy, 42:13
- treatment response, sleep, 42:13
- treatment response, social phobia, 44:33

**Affective disorder** continued

- Tridimensional Personality Questionnaire, manic symptoms, 41:215
- Tridimensional Personality Questionnaire, psychotic symptoms, 41:215
- triiodothyronine, melancholia, 42:73
- triiodothyronine, thyrotropin, 42:73
- triiodothyronine, thyroxine, 42:73
- tryptophan, amino acids in plasma, 44:91
- tryptophan, obsessive-compulsive disorder, 44:91
- whole blood measurement, ion selective electrode, 44:71
- whole blood measurement, lithium, 44:71

**Aging**

- chronic medical illness burden, depression, 41:237
- chronic medical illness burden, geropsychiatry, 41:237
- depression, chronic medical illness burden, 41:237
- depression, geropsychiatry, 41:237
- geropsychiatry, chronic medical illness burden, 41:237
- geropsychiatry, depression, 41:237

**Alzheimer's disease**

- Blessed dementia scale, memory, 44:167
- diagnosis, neuropsychological tests, 44:93
- dopamine uptake, platelets, 41:17
- longitudinal course, memory, 42:101
- longitudinal course, sex differences, 42:101
- memory, Blessed dementia scale, 44:167
- memory, longitudinal course, 42:101
- memory, sex differences, 42:101
- neuropsychological tests, diagnosis, 44:93
- platelets, dopamine uptake, 41:17
- sex differences, longitudinal course, 42:101
- sex differences, memory, 42:101

**Antidepressants**

- ACTH, cortisol, 41:45
- ACTH, glucose, 41:45
- ACTH, imipramine, 41:45
- ACTH, insulin tolerance test, 41:45
- ACTH, normal subjects, 41:45
- adenosyl-L-methionine, affective disorder, 44:257
- adenosyl-L-methionine, imipramine, 44:257
- adiazolam, affective disorder, 43:177
- adiazolam, desimpramine, 43:177
- adiazolam, melatonin, 43:177
- affective disorder, adenosyl-L-methionine, 44:257
- affective disorder, adiazolam, 43:177
- affective disorder, clinical features, 41:203

**Antidepressants** continued

affective disorder, desipramine, 43:177, 44:257  
 affective disorder, imipramine, 44:257  
 affective disorder, melatonin, 43:177  
 affective disorder, placebo, 41:203  
 affective disorder, response, 41:203  
 clinical features, affective disorder, 41:203  
 clinical features, placebo, 41:203  
 clinical features, response, 41:203  
 cortisol, ACTH, 41:45  
 cortisol, glucose, 41:45  
 cortisol, imipramine, 41:45  
 cortisol, insulin tolerance test, 41:45  
 cortisol, normal subjects, 41:45  
 desipramine, adinazolam, 43:177  
 desipramine, affective disorder, 43:177, 44:237  
 desipramine, melatonin, 43:177  
 glucose, ACTH, 41:45  
 glucose, cortisol, 41:45  
 glucose, imipramine, 41:45  
 glucose, insulin tolerance test, 41:45  
 glucose, normal subjects, 41:45  
 imipramine, ACTH, 41:45  
 imipramine, adenosyl-L-methionine, 44:257  
 imipramine, affective disorder, 44:257  
 imipramine, cortisol, 41:45  
 imipramine, glucose, 41:45  
 imipramine, insulin tolerance test, 41:45  
 imipramine, normal subjects, 41:45  
 insulin tolerance test, ACTH, 41:45  
 insulin tolerance test, cortisol, 41:45  
 insulin tolerance test, glucose, 41:45  
 insulin tolerance test, imipramine, 41:45  
 insulin tolerance test, normal subjects, 41:45  
 melatonin, adinazolam, 43:177  
 melatonin, affective disorder, 43:177  
 melatonin, desipramine, 43:177  
 normal subjects, ACTH, 41:45  
 normal subjects, cortisol, 41:45  
 normal subjects, glucose, 41:45  
 normal subjects, imipramine, 41:45  
 normal subjects, insulin tolerance test, 41:45  
 placebo, affective disorder, 41:203  
 placebo, clinical features, 41:203  
 placebo, response, 41:203  
 response, affective disorder, 41:203  
 response, clinical features, 41:203  
 response, placebo, 41:203

**Beta-endorphin**

ACTH, adolescents, 41:179  
 ACTH, exercise, 41:179  
 adolescents, ACTH, 41:179  
 adolescents, exercise, 41:179  
 affective disorder, immunology, 43:111

**Beta-endorphin** continued

affective disorder, natural killer cells, 43:111  
 exercise, ACTH, 41:179  
 exercise, adolescents, 41:179  
 immunology, affective disorder, 43:111  
 immunology, natural killer cells, 43:111  
 natural killer cells, affective disorder, 43:111  
 natural killer cells, immunology, 43:111

**Blood pressure**

adrenergic receptor, affective disorder, 41:257  
 adrenergic receptor, clonidine, 41:257  
 adrenergic receptor, depressive symptoms, 41:257  
 adrenergic receptor, electroconvulsive therapy, 41:257  
 adrenergic receptor, growth hormone, 41:257  
 affective disorder, adrenergic receptor, 41:257  
 affective disorder, clonidine, 41:257, 43:199  
 affective disorder, depressive symptoms, 41:257  
 affective disorder, electroconvulsive therapy, 41:257  
 affective disorder, growth hormone, 41:257  
 affective disorder, heart rate, 43:199  
 affective disorder, MHPG, 43:199  
 affective disorder, norepinephrine, 43:199  
 clonidine, adrenergic receptor, 41:257  
 clonidine, affective disorder, 41:257, 43:199  
 clonidine, depressive symptoms, 41:257  
 clonidine, electroconvulsive therapy, 41:257  
 clonidine, growth hormone, 41:257  
 clonidine, heart rate, 43:199  
 clonidine, MHPG, 43:199  
 clonidine, norepinephrine, 43:199  
 depressive symptoms, adrenergic receptor, 41:257  
 depressive symptoms, affective disorder, 41:257  
 depressive symptoms, clonidine, 41:257  
 depressive symptoms, electroconvulsive therapy, 41:257  
 depressive symptoms, growth hormone, 41:257  
 electroconvulsive therapy, adrenergic receptor, 41:257  
 electroconvulsive therapy, affective disorder, 41:257  
 electroconvulsive therapy, clonidine, 41:257  
 electroconvulsive therapy, depressive symptoms, 41:257  
 electroconvulsive therapy, growth hormone, 41:257  
 growth hormone, adrenergic receptor, 41:257  
 growth hormone, affective disorder, 41:257  
 growth hormone, clonidine, 41:257  
 growth hormone, depressive symptoms, 41:257  
 growth hormone, electroconvulsive therapy, 41:257

**Blood pressure continued**

heart rate, affective disorder, 43:199  
 heart rate, clonidine, 43:199  
 heart rate, MHPG, 43:199  
 heart rate, norepinephrine, 43:199  
 MHPG, affective disorder, 43:199  
 MHPG, clonidine, 43:199  
 MHPG, heart rate, 43:199  
 MHPG, norepinephrine, 43:199  
 norepinephrine, affective disorder, 43:199  
 norepinephrine, clonidine, 43:199  
 norepinephrine, heart rate, 43:199  
 norepinephrine, MHPG, 43:199

**Circadian rhythms**

affective disorder, depressed mood, 43:147  
 affective disorder, phototherapy, 43:147  
 affective disorder, seasonal depression, 43:147  
 affective disorder, social activity, 42:221  
 cortisol, melatonin, 43:161  
 cortisol, platelet serotonin uptake, 43:161  
 cortisol, prolactin, 43:161  
 cortisol, serotonin, 43:161  
 depressed mood, affective disorder, 43:147  
 depressed mood, phototherapy, 43:147  
 depressed mood, seasonal depression, 43:147  
 growth hormone, schizophrenia, 41:155  
 growth hormone, sleep, 41:155  
 melatonin, cortisol, 43:161  
 melatonin, platelet serotonin uptake, 43:161  
 melatonin, prolactin, 43:161  
 melatonin, serotonin, 43:161  
 phototherapy, affective disorder, 43:147  
 phototherapy, depressed mood, 43:147  
 phototherapy, seasonal depression, 43:147  
 platelet serotonin uptake, cortisol, 43:161  
 platelet serotonin uptake, melatonin, 43:161  
 platelet serotonin uptake, prolactin, 43:161  
 platelet serotonin uptake, serotonin, 43:161  
 prolactin, cortisol, 43:161  
 prolactin, melatonin, 43:161  
 prolactin, platelet serotonin uptake, 43:161  
 prolactin, serotonin, 43:161  
 schizophrenia, growth hormone, 41:155  
 schizophrenia, sleep, 41:155  
 seasonal depression, affective disorder, 43:147  
 seasonal depression, depressed mood, 43:147  
 seasonal depression, phototherapy, 43:147  
 serotonin, cortisol, 43:161  
 serotonin, melatonin, 43:161  
 serotonin, platelet serotonin uptake, 43:161  
 serotonin, prolactin, 43:161  
 sleep, growth hormone, 41:155  
 sleep, schizophrenia, 41:155  
 social activity, affective disorder, 42:221

**Clonidine**

adrenergic receptor, affective disorder, 41:257  
 adrenergic receptor, blood pressure, 41:257  
 adrenergic receptor, depressive symptoms, 41:257  
 adrenergic receptor, electroconvulsive therapy, 41:257  
 adrenergic receptor, growth hormone, 41:257  
 affective disorder, adrenergic receptor, 41:257  
 affective disorder, blood pressure, 41:257, 43:199  
 affective disorder, depressive symptoms, 41:257  
 affective disorder, electroconvulsive therapy, 41:257  
 affective disorder, growth hormone, 41:257  
 affective disorder, heart rate, 43:199  
 affective disorder, MHPG, 43:199  
 affective disorder, norepinephrine, 43:199  
 blood pressure, adrenergic receptor, 41:257  
 blood pressure, affective disorder, 41:257, 43:199  
 blood pressure, depressive symptoms, 41:257  
 blood pressure, electroconvulsive therapy, 41:257  
 blood pressure, growth hormone, 41:257  
 blood pressure, heart rate, 43:199  
 blood pressure, MHPG, 43:199  
 blood pressure, norepinephrine, 43:199  
 depressive symptoms, adrenergic receptor, 41:257  
 depressive symptoms, affective disorder, 41:257  
 depressive symptoms, blood pressure, 41:257  
 depressive symptoms, electroconvulsive therapy, 41:257  
 depressive symptoms, growth hormone, 41:257  
 electroconvulsive therapy, adrenergic receptor, 41:257  
 electroconvulsive therapy, affective disorder, 41:257  
 electroconvulsive therapy, blood pressure, 41:257  
 electroconvulsive therapy, depressive symptoms, 41:257  
 electroconvulsive therapy, growth hormone, 41:257  
 growth hormone, adrenergic receptor, 41:257  
 growth hormone, affective disorder, 41:257  
 growth hormone, blood pressure, 41:257  
 growth hormone, depressive symptoms, 41:257  
 growth hormone, electroconvulsive therapy, 41:257  
 heart rate, affective disorder, 43:199

**Clonidine** continued

heart rate, blood pressure, 43:199  
 heart rate, MHPG, 43:199  
 heart rate, norepinephrine, 43:199  
 MHPG, affective disorder, 43:199  
 MHPG, blood pressure, 43:199  
 MHPG, heart rate, 43:199  
 MHPG, norepinephrine, 43:199  
 norepinephrine, affective disorder, 43:199  
 norepinephrine, blood pressure, 43:199  
 norepinephrine, heart rate, 43:199  
 norepinephrine, MHPG, 43:199

**Clozapine**

electroencephalography, epileptic seizures, 44:107  
 electroencephalography, schizophrenia, 44:107  
 epileptic seizures, electroencephalography, 44:107

epileptic seizures, schizophrenia, 44:107  
 eye movements, neuroleptics, 41:25  
 eye movements, saccadic intrusions, 41:25  
 eye movements, schizophrenia, 41:25  
 neuroleptics, eye movements, 41:25  
 neuroleptics, saccadic intrusions, 41:25  
 neuroleptics, schizophrenia, 41:25  
 saccadic intrusions, eye movements, 41:25  
 saccadic intrusions, neuroleptics, 41:25  
 saccadic intrusions, schizophrenia, 41:25  
 schizophrenia, electroencephalography, 44:107  
 schizophrenia, epileptic seizures, 44:107  
 schizophrenia, eye movements, 41:25  
 schizophrenia, neuroleptics, 41:25  
 schizophrenia, saccadic intrusions, 41:25

**Cortisol**

ACTH, antidepressants, 41:45  
 ACTH, glucose, 41:45  
 ACTH, imipramine, 41:45  
 ACTH, insulin tolerance test, 41:45  
 ACTH, normal subjects, 41:45  
 affective disorder, age, 44:9  
 affective disorder, desipramine, 43:65, 44:237  
 affective disorder, dexamethasone suppression test, 44:9, 44:63,  
 affective disorder, dopamine, 43:31  
 affective disorder, epinephrine in urine, 43:31  
 affective disorder, fenfluramine, 43:137  
 affective disorder, magnetic resonance imaging, 44:63  
 affective disorder, MCPP, 43:65  
 affective disorder, melancholia, 43:137  
 affective disorder, monoamine oxidase, 44:1  
 affective disorder, norepinephrine, 43:65  
 affective disorder, norepinephrine in urine, 43:31

**Cortisol**

affective disorder, object loss, 44:227  
 affective disorder, panic disorder, 43:65  
 affective disorder, pituitary volume, 44:63  
 affective disorder, prolactin, 43:137  
 affective disorder, schizophrenia, 44:1  
 affective disorder, serotonin, 43:65, 43:137  
 affective disorder, sex differences, 44:9  
 affective disorder, suicide, 43:31  
 age, affective disorder, 44:9  
 age, dexamethasone suppression test, 44:9  
 age, sex differences, 44:9  
 aggression, childhood disorders, 43:263  
 aggression, disruptive behavior disorder, 43:263  
 aggression, fenfluramine, 43:263  
 aggression, prolactin, 43:263  
 aggression, serotonin, 43:263  
 antidepressants, ACTH, 41:45  
 antidepressants, glucose, 41:45  
 antidepressants, insulin tolerance test, 41:45  
 antidepressants, normal subjects, 41:45  
 attention deficit disorder, childhood disorders, 42:65  
 attention deficit disorder, disruptive behavior disorders, 42:65  
 attention deficit disorder, fenfluramine challenge, 42:65  
 attention deficit disorder, prolactin, 42:65  
 childhood disorders, aggression, 43:263  
 childhood disorders, attention deficit disorder, 42:65  
 childhood disorders, disruptive behavior disorder, 42:65, 43:263  
 childhood disorders, fenfluramine, 43:263  
 childhood disorders, fenfluramine challenge, 42:65  
 childhood disorders, prolactin, 42:65, 43:263  
 childhood disorders, serotonin, 43:263  
 circadian rhythms, melatonin, 43:161  
 circadian rhythms, platelet serotonin uptake, 43:161  
 circadian rhythms, prolactin, 43:161  
 circadian rhythms, serotonin, 43:161  
 desipramine, affective disorder, 43:65, 44:237  
 desipramine, MCPP, 43:65  
 desipramine, norepinephrine, 43:65  
 desipramine, panic disorder, 43:65  
 desipramine, serotonin, 43:65  
 dexamethasone suppression test, affective disorder, 44:9, 44:63, 44:227  
 dexamethasone suppression test, age, 44:9  
 dexamethasone suppression test, magnetic resonance imaging, 44:63

**Cortisol** continued

dexamethasone suppression test, object loss, 44:227  
 dexamethasone suppression test, pituitary volume, 44:63  
 dexamethasone suppression test, sex differences, 44:9  
 disruptive behavior disorder, aggression, 43:263  
 disruptive behavior disorder, attention deficit disorder, 42:65  
 disruptive behavior disorder, childhood disorders, 42:65, 43:263  
 disruptive behavior disorder, fenfluramine, 43:263  
 disruptive behavior disorder, fenfluramine challenge, 42:65  
 disruptive behavior disorder, prolactin, 42:65, 43:263  
 disruptive behavior disorder, serotonin, 43:263  
 dopamine, affective disorder, 43:31  
 dopamine, epinephrine in urine, 43:31  
 dopamine, norepinephrine in urine, 43:31  
 dopamine, suicide, 43:31  
 epinephrine in urine, affective disorder, 43:31  
 epinephrine in urine, dopamine, 43:31  
 epinephrine in urine, norepinephrine in urine, 43:31  
 epinephrine in urine, suicide, 43:31  
 fenfluramine, affective disorder, 43:137  
 fenfluramine, aggression, 43:263  
 fenfluramine challenge, attention deficit disorder, 42:65  
 fenfluramine challenge, childhood disorders, 42:65  
 fenfluramine challenge, disruptive behavior disorder, 42:65  
 fenfluramine challenge, prolactin, 42:65  
 fenfluramine, childhood disorders, 43:263  
 fenfluramine, disruptive behavior disorder, 43:263  
 fenfluramine, melancholia, 43:137  
 fenfluramine, prolactin, 43:137, 43:263  
 fenfluramine, serotonin, 43:137, 43:263  
 glucose, ACTH, 41:45  
 glucose, antidepressants, 41:45  
 glucose, imipramine, 41:45  
 glucose, insulin tolerance test, 41:45  
 glucose, normal subjects, 41:45  
 imipramine, ACTH, 41:45  
 imipramine, antidepressants, 41:45  
 imipramine, glucose, 41:45  
 imipramine, insulin tolerance test, 41:45  
 imipramine, normal subjects, 41:45

**Cortisol** continued

insulin tolerance test, ACTH, 41:45  
 insulin tolerance test, antidepressants, 41:45  
 insulin tolerance test, glucose, 41:45  
 insulin tolerance test, imipramine, 41:45  
 insulin tolerance test, normal subjects, 41:45  
 magnetic resonance imaging, affective disorder, 44:63  
 magnetic resonance imaging, dexamethasone suppression test, 44:63  
 magnetic resonance imaging, pituitary volume, 44:63  
 MCPP, affective disorder, 43:65  
 MCPP, desipramine, 43:65  
 MCPP, norepinephrine, 43:65  
 MCPP, panic disorder, 43:65  
 MCPP, serotonin, 43:65  
 melancholia, affective disorder, 43:137  
 melancholia, fenfluramine, 43:137  
 melancholia, prolactin, 43:137  
 melancholia, serotonin, 43:137  
 melatonin, circadian rhythms, 43:161  
 melatonin, obsessive-compulsive disorder, 44:217  
 melatonin, platelet serotonin uptake, 43:161  
 melatonin, prolactin, 43:161  
 melatonin, serotonin, 43:161  
 monoamine oxidase, affective disorder, 44:1  
 monoamine oxidase, schizophrenia, 44:1  
 norepinephrine, affective disorder, 43:65  
 norepinephrine, desipramine, 43:65  
 norepinephrine in urine, affective disorder, 43:31  
 norepinephrine in urine, dopamine, 43:31  
 norepinephrine in urine, epinephrine in urine, 43:31  
 norepinephrine in urine, suicide, 43:31  
 norepinephrine, MCPP, 43:65  
 norepinephrine, panic disorder, 43:65  
 norepinephrine, serotonin, 43:65  
 normal subjects, ACTH, 41:45  
 normal subjects, antidepressants, 41:45  
 normal subjects, glucose, 41:45  
 normal subjects, imipramine, 41:45  
 normal subjects, insulin tolerance test, 41:45  
 object loss, affective disorder, 44:227  
 object loss, dexamethasone suppression test, 44:227  
 obsessive-compulsive disorder, melatonin, 44:217  
 panic disorder, affective disorder, 43:65  
 panic disorder, desipramine, 43:65  
 panic disorder, MCPP, 43:65  
 panic disorder, norepinephrine, 43:65

**Cortisol** continued

panic disorder, serotonin, 43:65  
 pituitary volume, affective disorder, 44:63  
 pituitary volume, dexamethasone suppression test, 44:63  
 pituitary volume, magnetic resonance imaging, 44:63  
 platelet serotonin uptake, circadian rhythms, 43:161  
 platelet serotonin uptake, melatonin, 43:161  
 platelet serotonin uptake, prolactin, 43:161  
 platelet serotonin uptake, serotonin, 43:161  
 prolactin, affective disorder, 43:137  
 prolactin, aggression, 43:263  
 prolactin, attention deficit disorder, 42:65  
 prolactin, childhood disorders, 42:65, 43:263  
 prolactin, circadian rhythms, 43:161  
 prolactin, disruptive behavior disorder, 42:65, 43:263  
 prolactin, fenfluramine, 43:137, 43:263  
 prolactin, fenfluramine challenge, 42:65  
 prolactin, melancholia, 43:137  
 prolactin, melatonin, 43:161  
 prolactin, platelet serotonin uptake, 43:161  
 prolactin, serotonin, 43:137, 43:161, 43:263  
 schizophrenia, affective disorder, 44:1  
 schizophrenia, monoamine oxidase, 44:1  
 serotonin, affective disorder, 43:65, 43:137  
 serotonin, aggression, 43:263  
 serotonin, childhood disorders, 43:263  
 serotonin, circadian rhythms, 43:161  
 serotonin, desipramine, 43:65  
 serotonin, disruptive behavior disorder, 43:263  
 serotonin, fenfluramine, 43:137, 43:263  
 serotonin, MCPP, 43:65  
 serotonin, melancholia, 43:137  
 serotonin, melatonin, 43:161  
 serotonin, norepinephrine, 43:65  
 serotonin, panic disorder, 43:65  
 serotonin, platelet serotonin uptake, 43:161  
 serotonin, prolactin, 43:137, 43:161, 43:263  
 sex differences, affective disorder, 44:9  
 sex differences, age, 44:9  
 sex differences, dexamethasone suppression test, 44:9  
 suicide, affective disorders, 43:31  
 suicide, dopamine, 43:31  
 suicide, epinephrine in urine, 43:31  
 suicide, norepinephrine in urine, 43:31

**Dementia**

agitation, scale for assessment, 41:73  
 scale for assessment, agitation, 41:73

**Diazepam**

heart rate, norepinephrine, 41:89  
 heart rate, normal men, 41:89  
 heart rate, vagal tone, 41:89  
 norepinephrine, heart rate, 41:89  
 norepinephrine, normal men, 41:89  
 norepinephrine, vagal tone, 41:89  
 normal men, heart rate, 41:89  
 normal men, norepinephrine, 41:89  
 normal men, vagal tone, 41:89  
 vagal tone, heart rate, 41:89  
 vagal tone, norepinephrine, 41:89  
 vagal tone, normal men, 41:89

**Dopamine**

affective disorder, cortisol, 43:31  
 affective disorder, epinephrine in urine, 43:31  
 affective disorder, norepinephrine in urine, 43:31  
 affective disorder, suicide, 43:31  
 Alzheimer's disease, platelets, 41:17  
 cortisol, affective disorder, 43:31  
 cortisol, epinephrine in urine, 43:31  
 cortisol, norepinephrine in urine, 43:31  
 cortisol, suicide, 43:31  
 delusional state, platelets, 41:17  
 delusional state, schizophrenia, 41:17  
 domperidone, growth hormone, 42:159  
 domperidone, prolactin, 42:159  
 domperidone, schizophrenia, 42:159  
 epinephrine in urine, affective disorder, 43:31  
 epinephrine in urine, cortisol, 43:31  
 epinephrine in urine, norepinephrine in urine, 43:31  
 epinephrine in urine, suicide, 43:31  
 growth hormone, domperidone, 42:159  
 growth hormone, prolactin, 42:159  
 growth hormone, schizophrenia, 42:159  
 norepinephrine in urine, affective disorder, 43:31  
 norepinephrine in urine, cortisol, 43:31  
 norepinephrine in urine, epinephrine in urine, 43:31  
 norepinephrine in urine, suicide, 43:31  
 platelets, Alzheimer's disease, 41:17  
 platelets, delusional state, 41:17  
 platelets, schizophrenia, 41:17  
 prolactin, domperidone, 42:159  
 prolactin, growth hormone, 42:159  
 prolactin, schizophrenia, 42:159  
 schizophrenia, delusional state, 41:17  
 schizophrenia, domperidone, 42:159  
 schizophrenia, growth hormone, 42:159  
 schizophrenia, platelets, 41:17  
 schizophrenia, prolactin, 42:159

**Dopamine** continued

- suicide, affective disorder, 43:31
- suicide, cortisol, 43:31
- suicide, epinephrine in urine, 43:31
- suicide, norepinephrine in urine, 43:31

**Dyskinesia**

- abnormal-movement disorders, haloperidol, 41:191
- abnormal-movement disorders, homovanillic acid, 41:191
- abnormal-movement disorders, negative symptoms, 41:191
- abnormal-movement disorders, neuroleptics, 41:191
- abnormal-movement disorders, prolactin, 41:191
- abnormal-movement disorders, schizophrenia, 41:191
- haloperidol, abnormal-movement disorders, 41:191
- haloperidol, homovanillic acid, 41:191
- haloperidol, negative symptoms, 41:191
- haloperidol, neuroleptics, 41:191
- haloperidol, prolactin, 41:191
- haloperidol, schizophrenia, 41:191
- homovanillic acid, abnormal-movement disorders, 41:191
- homovanillic acid, haloperidol, 41:191
- homovanillic acid, negative symptoms, 41:191
- homovanillic acid, neuroleptics, 41:191
- homovanillic acid, prolactin, 41:191
- homovanillic acid, schizophrenia, 41:191
- homovanillic acid, side effects, 41:191
- negative symptoms, abnormal-movement disorders, 41:191
- negative symptoms, haloperidol, 41:191
- negative symptoms, homovanillic acid, 41:191
- negative symptoms, neuroleptics, 41:191
- negative symptoms, prolactin, 41:191
- negative symptoms, schizophrenia, 41:191
- neuroleptics, abnormal-movement disorders, 41:191
- neuroleptics, haloperidol, 41:191
- neuroleptics, homovanillic acid, 41:191
- neuroleptics, negative symptoms, 41:191
- neuroleptics, prolactin, 41:191
- neuroleptics, schizophrenia, 41:191
- prolactin, abnormal-movement disorders, 41:191
- prolactin, haloperidol, 41:191
- prolactin, homovanillic acid, 41:191
- prolactin, negative symptoms, 41:191
- prolactin, neuroleptics, 41:191
- prolactin, schizophrenia, 41:191

**Dyskinesia** continued

- schizophrenia, abnormal-movement disorders, 41:191

schizophrenia, haloperidol, 41:191

schizophrenia, homovanillic acid, 41:191

schizophrenia, negative symptoms, 41:191

schizophrenia, neuroleptics, 41:191

schizophrenia, prolactin, 41:191

**Electroconvulsive therapy**

- adrenergic receptor, affective disorder, 41:257

adrenergic receptor, blood pressure, 41:257

adrenergic receptor, clonidine, 41:257

adrenergic receptor, depressive symptoms, 41:257

adrenergic receptor, growth hormone, 41:257

affective disorder, adrenergic receptor, 41:257

affective disorder, blood pressure, 41:257

affective disorder, clonidine, 41:257

affective disorder, growth hormone, 41:257

blood pressure, adrenergic receptor, 41:257

blood pressure, affective disorder, 41:257

blood pressure, clonidine, 41:257

blood pressure, depressive symptoms, 41:257

blood pressure, growth hormone, 41:257

clonidine, adrenergic receptor, 41:257

clonidine, affective disorder, 41:257

clonidine, blood pressure, 41:257

clonidine, depressive symptoms, 41:257

clonidine, growth hormone, 41:257

depressive symptoms, adrenergic receptor, 41:257

depressive symptoms, blood pressure, 41:257

depressive symptoms, clonidine, 41:257

depressive symptoms, growth hormone, 41:257

growth hormone, adrenergic receptor, 41:257

growth hormone, affective disorder, 41:257

growth hormone, blood pressure, 41:257

growth hormone, clonidine, 41:257

growth hormone, depressive symptoms, 41:257

**Evoked potentials**

- affective disorder, augmenting-reducing, 44:181

affective disorder, lithium, 44:181

augmenting-reducing, affective disorder, 44:181

augmenting-reducing, lithium, 44:181

eye movements, schizophrenia, 41:227

lithium, affective disorder, 44:181

lithium, augmenting-reducing, 44:181

MHPG, norepinephrine, 44:21

MHPG, schizophrenia, 44:21

MHPG, sensory gating, 44:21

norepinephrine, MHPG, 44:21

**Evoked potentials** continued  
 norepinephrine, schizophrenia, 44:21  
 norepinephrine, sensory gating, 44:21  
 schizophrenia, eye movements, 41:227  
 schizophrenia, MHPG, 44:21  
 schizophrenia, norepinephrine, 44:21  
 schizophrenia, sensory gating, 44:21  
 sensory gating, MHPG, 44:21  
 sensory gating, norepinephrine, 44:21  
 sensory gating, schizophrenia, 44:21

**Exercise**  
 ACTH, adolescents, 41:179  
 ACTH, beta-endorphin, 41:179  
 adolescents, ACTH, 41:179  
 adolescents, beta-endorphin, 41:179  
 beta-endorphin, ACTH, 41:179  
 beta-endorphin, adolescents, 41:179

**Expressed emotion**  
 content analysis, family interview, 41:275  
 content analysis, relapse prediction, 41:275  
 content analysis, schizophrenia, 41:275  
 family interview, content analysis, 41:275  
 family interview, relapse prediction, 41:275  
 family interview, schizophrenia, 41:275  
 relapse prediction, content analysis, 41:275  
 relapse prediction, family interview, 41:275  
 relapse prediction, schizophrenia, 41:275  
 schizophrenia, content analysis, 41:275  
 schizophrenia, family interview, 41:275  
 schizophrenia, relapse prediction, 41:275

**Eye movements**  
 affective disorder, paranoid subtype, 43:93  
 affective disorder, saccades, 43:93  
 affective disorder, schizophrenia, 43:93  
 clozapine, neuroleptics, 41:25  
 clozapine, saccadic intrusions, 41:25  
 clozapine, schizophrenia, 41:25  
 evoked potentials, schizophrenia, 41:227  
 hand preference, intelligence, 41:115  
 hand preference, laterality, 41:115  
 hand preference, neuropsychological tests, 41:115  
 hand preference, normal men, 41:115  
 hand preference, schizotypy, 41:115  
 intelligence, hand preference, 41:115  
 intelligence, laterality, 41:115  
 intelligence, neuropsychological tests, 41:115  
 intelligence, normal men, 41:115  
 intelligence, schizotypy, 41:115  
 laterality, hand preference, 41:115  
 laterality, intelligence, 41:115  
 laterality, neuropsychological tests, 41:115  
 laterality, normal men, 41:115  
 laterality, schizotypy, 41:115

**Eye movements** continued  
 neuroleptics, clozapine, 41:25  
 neuroleptics, saccadic intrusions, 41:25  
 neuroleptics, schizophrenia, 41:25  
 neuropsychological tests, hand preference, 41:115  
 neuropsychological tests, intelligence, 41:115  
 neuropsychological tests, laterality, 41:115  
 neuropsychological tests, normal men, 41:115  
 neuropsychological tests, schizotypy, 41:115  
 normal men, hand preference, 41:115  
 normal men, intelligence, 41:115  
 normal men, laterality, 41:115  
 normal men, neuropsychological tests, 41:115  
 normal men, schizotypy, 41:115  
 obsessive-compulsive disorder, smooth pursuit, 42:1  
 paranoid subtype, affective disorder, 43:93  
 paranoid subtype, saccades, 43:93  
 paranoid subtype, schizophrenia, 43:93  
 saccades, affective disorder, 43:93  
 saccades, paranoid subtype, 43:93  
 saccades, schizophrenia, 43:93  
 saccadic intrusions, clozapine, 41:25  
 saccadic intrusions, neuroleptics, 41:25  
 saccadic intrusions, schizophrenia, 41:25  
 schizophrenia, affective disorder, 43:93  
 schizophrenia, clozapine, 41:25  
 schizophrenia, evoked potentials, 41:227  
 schizophrenia, neuroleptics, 41:25  
 schizophrenia, paranoid subtype, 43:93  
 schizophrenia, saccades, 43:93  
 schizophrenia, saccadic intrusions, 41:25  
 schizotypy, hand preference, 41:115  
 schizotypy, intelligence, 41:115  
 schizotypy, laterality, 41:115  
 schizotypy, neuropsychological tests, 41:115  
 schizotypy, normal men, 41:115  
 smooth pursuit, obsessive-compulsive disorder, 42:1

**Family studies**  
 adolescent depression, childhood depression, 41:53  
 adolescent depression, polysomnography, 41:53  
 adolescent depression, sleep, 41:53  
 affective disorder, adolescent depression, 41:53  
 affective disorder, childhood depression, 41:53  
 affective disorder, polysomnography, 41:53  
 affective disorder, sleep, 41:53  
 childhood depression, adolescent depression, 41:53

**Family studies** continued  
 childhood depression, polysomnography, 41:53  
 childhood depression, sleep, 41:53  
 polysomnography, adolescent depression, 41:53  
 polysomnography, affective disorder, 41:53  
 polysomnography, childhood depression, 41:53  
 polysomnography, sleep, 41:53  
 sleep, adolescent depression, 41:53  
 sleep, affective disorder, 41:53  
 sleep, childhood depression, 41:53  
 sleep, polysomnography, 41:53

**Frontal lobe**  
 color naming, neuropsychological tests, 41:137  
 color naming, schizophrenia, 41:137  
 color naming, Stroop task, 41:137  
 neuropsychological tests, color naming, 41:137  
 neuropsychological tests, schizophrenia, 41:137  
 schizophrenia, color naming, 41:137  
 schizophrenia, neuropsychological tests, 41:137  
 schizophrenia, Stroop task, 41:137  
 Stroop task, color naming, 41:137  
 Stroop task, schizophrenia, 41:137

**Genetics**  
 affective disorder, comorbidity, 42:111  
 affective disorder, obsessive-compulsive disorder, 42:111  
 age of onset, diagnostic subtypes, 41:107  
 age of onset, schizophrenia, 41:107  
 age of onset, siblings, 41:107  
 assortative mating, schizotypal personality disorder, 41:283  
 attention, high-risk study, 44:125  
 attention, reaction time, 44:125  
 attention, schizophrenia, 44:125  
 chromosome 5, schizophrenia, 44:171  
 comorbidity, affective disorder, 42:111  
 comorbidity, obsessive-compulsive disorder, 42:111  
 diagnostic subtypes, age of onset, 41:107  
 diagnostic subtypes, schizophrenia, 41:107  
 diagnostic subtypes, siblings, 41:107  
 high-risk study, attention, 44:125  
 high-risk study, reaction time, 44:125  
 high-risk study, schizophrenia, 44:125  
 HLA, linkage, 41:99  
 HLA, multiplex families, 41:99  
 HLA, schizophrenia, 41:99  
 linkage, HLA, 41:99  
 linkage, multiplex families, 41:99  
 linkage, schizophrenia, 41:99  
 multiplex families, HLA, 41:99  
 multiplex families, linkage, 41:99

**Genetics** continued  
 multiplex families, schizophrenia, 41:99  
 obsessive-compulsive disorder, affective disorder, 42:111  
 obsessive-compulsive disorder, comorbidity, 42:111  
 pupillometry, twin studies, 43:299  
 reaction time, attention, 44:125  
 reaction time, high-risk study, 44:125  
 reaction time, schizophrenia, 44:125  
 schizophrenia, age of onset, 41:107  
 schizophrenia, attention, 44:125  
 schizophrenia, chromosome 5, 44:171  
 schizophrenia, diagnostic subtypes, 41:107  
 schizophrenia, high-risk study, 44:125  
 schizophrenia, HLA, 41:99  
 schizophrenia, linkage, 41:99  
 schizophrenia, multiplex families, 41:99  
 schizophrenia, reaction time, 44:125  
 schizophrenia, siblings, 41:107  
 schizotypal personality disorder, assortative mating, 41:283  
 siblings, age of onset, 41:107  
 siblings, diagnostic subtypes, 41:107  
 siblings, schizophrenia, 41:107  
 twin studies, pupillometry, 43:299

**Geropsychiatry**  
 aging, chronic medical illness burden, 41:237  
 aging, depression, 41:237  
 chronic medical illness burden, aging, 41:237  
 chronic medical illness burden, depression, 41:237  
 depression, aging, 41:237  
 depression, chronic medical illness burden, 41:237

**Glucose**  
 ACTH, antidepressants, 41:45  
 ACTH, cortisol, 41:45  
 ACTH, imipramine, 41:45  
 ACTH, insulin tolerance test, 41:45  
 ACTH, normal subjects, 41:45  
 antidepressants, ACTH, 41:45  
 antidepressants, cortisol, 41:45  
 antidepressants, insulin tolerance test, 41:45  
 antidepressants, normal subjects, 41:45  
 cortisol, ACTH, 41:45  
 cortisol, antidepressants, 41:45  
 cortisol, imipramine, 41:45  
 cortisol, insulin tolerance test, 41:45  
 cortisol, normal subjects, 41:45  
 imipramine, ACTH, 41:45  
 imipramine, cortisol, 41:45  
 imipramine, insulin tolerance test, 41:45  
 imipramine, normal subjects, 41:45

**Glucose** continued

insulin tolerance test, ACTH, 41:45  
 insulin tolerance test, antidepressants, 41:45  
 insulin tolerance test, cortisol, 41:45  
 insulin tolerance test, imipramine, 41:45  
 insulin tolerance test, normal subjects, 41:45  
 normal subjects, ACTH, 41:45  
 normal subjects, antidepressants, 41:45  
 normal subjects, cortisol, 41:45  
 normal subjects, imipramine, 41:45  
 normal subjects, insulin tolerance test, 41:45

**Growth hormone**

abstinence, carbidopa treatment, 43:77  
 abstinence, cocaine, 43:77  
 abstinence, homovanillic acid, 43:77  
 abstinence, MHPG, 43:77  
 abstinence, prolactin, 43:77  
 abstinence, substance abuse, 43:77  
 adrenergic receptor, affective disorder, 41:257  
 adrenergic receptor, blood pressure, 41:257  
 adrenergic receptor, clonidine, 41:257  
 adrenergic receptor, depressive symptoms, 41:257  
 adrenergic receptor, electroconvulsive therapy, 41:257  
 affective disorder, adrenergic receptor, 41:257  
 affective disorder, blood pressure, 41:257  
 affective disorder, clonidine, 41:257  
 affective disorder, electroconvulsive therapy, 41:257  
 blood pressure, adrenergic receptor, 41:257  
 blood pressure, affective disorder, 41:257  
 blood pressure, clonidine, 41:257  
 blood pressure, depressive symptoms, 41:257  
 blood pressure, electroconvulsive therapy, 41:257  
 carbidopa treatment, abstinence, 43:77  
 carbidopa treatment, cocaine, 43:77  
 carbidopa treatment, homovanillic acid, 43:77  
 carbidopa treatment, MHPG, 43:77  
 carbidopa treatment, prolactin, 43:77  
 carbidopa treatment, substance abuse, 43:77  
 circadian rhythm, schizophrenia, 41:155  
 circadian rhythm, sleep, 41:155  
 clonidine, adrenergic receptor, 41:257  
 clonidine, affective disorder, 41:257  
 clonidine, blood pressure, 41:257  
 clonidine, depressive symptoms, 41:257  
 clonidine, electroconvulsive therapy, 41:257  
 cocaine, abstinence, 43:77  
 cocaine, carbidopa treatment, 43:77  
 cocaine, homovanillic acid, 43:77  
 cocaine, MHPG, 43:77  
 cocaine, prolactin, 43:77

**Growth hormone** continued

cocaine, substance abuse, 43:77  
 depressive symptoms, adrenergic receptor, 41:257  
 depressive symptoms, blood pressure, 41:257  
 depressive symptoms, clonidine, 41:257  
 depressive symptoms, electroconvulsive therapy, 41:257  
 domperidone, dopamine, 42:159  
 domperidone, prolactin, 42:159  
 domperidone, schizophrenia, 42:159  
 dopamine, domperidone, 42:159  
 dopamine, prolactin, 42:159  
 dopamine, schizophrenia, 42:159  
 electroconvulsive therapy, adrenergic receptor, 41:257  
 electroconvulsive therapy, affective disorder, 41:257  
 electroconvulsive therapy, blood pressure, 41:257  
 electroconvulsive therapy, clonidine, 41:257  
 electroconvulsive therapy, depressive symptoms, 41:257  
 homovanillic acid, abstinence, 43:77  
 homovanillic acid, carbidopa treatment, 43:77  
 homovanillic acid, cocaine, 43:77  
 homovanillic acid, MHPG, 43:77  
 homovanillic acid, prolactin, 43:77  
 homovanillic acid, substance abuse, 43:77  
 MHPG, abstinence, 43:77  
 MHPG, carbidopa treatment, 43:77  
 MHPG, cocaine, 43:77  
 MHPG, homovanillic acid, 43:77  
 MHPG, prolactin, 43:77  
 MHPG, substance abuse, 43:77  
 prolactin, abstinence, 43:77  
 prolactin, carbidopa treatment, 43:77  
 prolactin, cocaine, 43:77  
 prolactin, domperidone, 42:159  
 prolactin, dopamine, 42:159  
 prolactin, homovanillic acid, 43:77  
 prolactin, MHPG, 43:77  
 prolactin, schizophrenia, 42:159  
 prolactin, substance abuse, 43:77  
 schizophrenia, circadian rhythm, 41:155  
 schizophrenia, domperidone, 42:159  
 schizophrenia, dopamine, 42:159  
 schizophrenia, prolactin, 42:159  
 schizophrenia, sleep, 41:155  
 sleep, circadian rhythm, 41:155  
 sleep, schizophrenia, 41:155  
 substance abuse, abstinence, 43:77  
 substance abuse, carbidopa treatment, 43:77  
 substance abuse, cocaine, 43:77

**Growth hormone** continued

- substance abuse, homovanillic acid, 43:77
- substance abuse, MHPG, 43:77
- substance abuse, prolactin, 43:77

**Haloperidol**

- abnormal-movement disorders, dyskinesia, 41:191
- abnormal-movement disorders, homovanillic acid, 41:191
- abnormal-movement disorders, negative symptoms, 41:191
- abnormal-movement disorders, neuroleptics, 41:191
- abnormal-movement disorders, prolactin, 41:191
- abnormal-movement disorders, schizophrenia, 41:191
- dyskinesia, homovanillic acid, 41:191
- dyskinesia, negative symptoms, 41:191
- dyskinesia, prolactin, 41:191
- dyskinesia, schizophrenia, 41:191
- EEG, neuroleptics, 42:129
- EEG, schizophrenia, 42:129
- EEG, treatment response, 42:129
- homovanillic acid, abnormal-movement disorders, 41:191
- homovanillic acid, dyskinesia, 41:191
- homovanillic acid, negative symptoms, 41:191
- homovanillic acid, prolactin, 41:191
- homovanillic acid, schizophrenia, 41:191
- homovanillic acid, side effects, 41:191
- negative symptoms, abnormal-movement disorders, 41:191
- negative symptoms, dyskinesia, 41:191
- negative symptoms, homovanillic acid, 41:191
- negative symptoms, prolactin, 41:191
- negative symptoms, schizophrenia, 41:191
- negative symptoms, side effects, 41:191
- prolactin, abnormal-movement disorders, 41:191
- prolactin, dyskinesia, 41:191
- prolactin, homovanillic acid, 41:191
- prolactin, negative symptoms, 41:191
- prolactin, schizophrenia, 41:191
- prolactin, side effects, 41:191
- pupillometry, relapse, 43:287
- pupillometry, schizophrenia, 43:287
- relapse, pupillometry, 43:287
- relapse, schizophrenia, 43:287
- schizophrenia, abnormal-movement disorders, 41:191
- schizophrenia, dyskinesia, 41:191
- schizophrenia, EEG, 42:129
- schizophrenia, homovanillic acid, 41:191

**Haloperidol** continued

- schizophrenia, negative symptoms, 41:191
- schizophrenia, prolactin, 41:191
- schizophrenia, pupillometry, 43:287
- schizophrenia, relapse, 43:287
- schizophrenia, side effects, 41:191
- schizophrenia, treatment response, 42:129
- side effects, homovanillic acid, 41:191
- side effects, negative symptoms, 41:191
- side effects, prolactin, 41:191
- side effects, schizophrenia, 41:191
- treatment response, EEG, 42:129
- treatment response, schizophrenia, 42:129

**5-HIAA** (5-hydroxyindoleacetic acid)

- indole-3-acetic acid, obsessive-compulsive disorder, 41:267
- indole-3-acetic acid, serotonin, 41:267
- indole-3-acetic acid, Tourette's syndrome, 41:267
- indole-3-acetic acid, tryptamine, 41:267

**obsessive-compulsive disorder**, indole-3-acetic acid, 41:267

- obsessive-compulsive disorder, serotonin, 41:267
- obsessive-compulsive disorder, Tourette's syndrome, 41:267
- obsessive-compulsive disorder, tryptamine, 41:267
- serotonin, indole-3-acetic acid, 41:267
- serotonin, obsessive-compulsive disorder, 41:267
- serotonin, Tourette's syndrome, 41:267
- serotonin, tryptamine, 41:267

**Tourette's syndrome**, indole-3-acetic acid, 41:267

- Tourette's syndrome, obsessive-compulsive disorder, 41:267
- Tourette's syndrome, serotonin, 41:267
- Tourette's syndrome, tryptamine, 41:267
- tryptamine, indole-3-acetic acid, 41:267
- tryptamine, obsessive-compulsive disorder, 41:267
- tryptamine, serotonin, 41:267
- tryptamine, Tourette's syndrome, 41:267

**Heart rate**

- affective disorder, blood pressure, 43:199
- affective disorder, clonidine, 43:199
- affective disorder, MHPG, 43:199
- affective disorder, norepinephrine, 43:199
- blood pressure, affective disorder, 43:199
- blood pressure, clonidine, 43:199
- blood pressure, MHPG, 43:199
- blood pressure, norepinephrine, 43:199
- clonidine, affective disorder, 43:199

**Heart rate continued**

clonidine, blood pressure, 43:199  
 clonidine, MHPG, 43:199  
 clonidine, norepinephrine, 43:199  
 diazepam, norepinephrine, 41:89  
 diazepam, normal men, 41:89  
 MHPG, affective disorder, 43:199  
 MHPG, blood pressure, 43:199  
 MHPG, clonidine, 43:199  
 MHPG, norepinephrine, 43:199  
 norepinephrine, affective disorder, 43:199  
 norepinephrine, blood pressure, 43:199  
 norepinephrine, clonidine, 43:199  
 norepinephrine, diazepam, 41:89  
 norepinephrine, MHPG, 43:199  
 norepinephrine, normal men, 41:89  
 norepinephrine, vagal tone, 41:89  
 normal men, diazepam, 41:89  
 normal men, norepinephrine, 41:89  
 normal men, vagal tone, 41:89  
 vagal tone, diazepam, 41:89  
 vagal tone, norepinephrine, 41:89  
 vagal tone, normal men, 41:89  
**HIV (human immunodeficiency virus)**  
 neuropsychological tests, substance abuse, 41:163  
 substance abuse, neuropsychological tests, 41:163  
**HLA (human leukocyte antigen)**  
 genetics, linkage, 41:99  
 genetics, multiplex families, 41:99  
 genetics, schizophrenia, 41:99  
 linkage, genetics, 41:99  
 linkage, multiplex families, 41:99  
 linkage, schizophrenia, 41:99  
 multiplex families, genetics, 41:99  
 multiplex families, linkage, 41:99  
 multiplex families, schizophrenia, 41:99  
 schizophrenia, genetics, 41:99  
 schizophrenia, linkage, 41:99  
 schizophrenia, multiplex families, 41:99  
**Homovanillic acid**  
 abnormal-movement disorders, haloperidol, 41:191  
 abnormal-movement disorders, negative symptoms, 41:191  
 abnormal-movement disorders, neuroleptics, 41:191  
 abnormal-movement disorders, prolactin, 41:191  
 abnormal-movement disorders, schizophrenia, 41:191  
 abstinence, carbidopa treatment, 43:77  
 abstinence, cocaine, 43:77

**Homovanillic acid continued**

abstinence, growth hormone, 43:77  
 abstinence, MHPG, 43:77  
 abstinence, prolactin, 43:77  
 abstinence, substance abuse, 43:77  
 carbidopa treatment, abstinence, 43:77  
 carbidopa treatment, cocaine, 43:77  
 carbidopa treatment, growth hormone, 43:77  
 carbidopa treatment, MHPG, 43:77  
 carbidopa treatment, prolactin, 43:77  
 carbidopa treatment, substance abuse, 43:77  
 cocaine, abstinence, 43:77  
 cocaine, carbidopa treatment, 43:77  
 cocaine, growth hormone, 43:77  
 cocaine, MHPG, 43:77  
 cocaine, prolactin, 43:77  
 cocaine, substance abuse, 43:77  
 dyskinesia, haloperidol, 41:191  
 dyskinesia, negative symptoms, 41:191  
 dyskinesia, neuroleptics, 41:191  
 dyskinesia, prolactin, 41:191  
 dyskinesia, schizophrenia, 41:191  
 fenfluramine, obsessive-compulsive disorder, 42:185  
 growth hormone, abstinence, 43:77  
 growth hormone, carbidopa treatment, 43:77  
 growth hormone, cocaine, 43:77  
 growth hormone, MHPG, 43:77  
 growth hormone, prolactin, 43:77  
 growth hormone, substance abuse, 43:77  
 haloperidol, abnormal-movement disorders, 41:191  
 haloperidol, dyskinesia, 41:191  
 haloperidol, negative symptoms, 41:191  
 haloperidol, neuroleptics, 41:191  
 haloperidol, prolactin, 41:191  
 haloperidol, schizophrenia, 41:191  
 haloperidol, side effects, 41:191  
 MHPG, abstinence, 43:77  
 MHPG, carbidopa treatment, 43:77  
 MHPG, cocaine, 43:77  
 MHPG, growth hormone, 43:77  
 MHPG, prolactin, 43:77  
 MHPG, substance abuse, 43:77  
 negative symptoms, abnormal-movement disorders, 41:191  
 negative symptoms, dyskinesia, 41:191  
 negative symptoms, haloperidol, 41:191  
 negative symptoms, neuroleptics, 41:191  
 negative symptoms, prolactin, 41:191  
 negative symptoms, schizophrenia, 41:191  
 negative symptoms, side effects, 41:191  
 neuroleptics, abnormal-movement disorders, 41:191

**Homovanillic acid** continued  
 neuroleptics, dyskinesia, 41:191  
 neuroleptics, negative symptoms, 41:191  
 neuroleptics, prolactin, 41:191  
 neuroleptics, schizophrenia, 41:191  
 neuroleptics, side effects, 41:191  
 neuropsychological tasks, Tourette's syndrome, 43:277  
 neuropsychological tasks, trace amines, 43:277  
 obsessive-compulsive disorder, fenfluramine, 42:185  
 prolactin, abnormal-movement disorders, 41:191  
 prolactin, abstinence, 43:77  
 prolactin, carbidopa treatment, 43:77  
 prolactin, cocaine, 43:77  
 prolactin, dyskinesia, 41:191  
 prolactin, growth hormone, 43:77  
 prolactin, haloperidol, 41:191  
 prolactin, MHPG, 43:77  
 prolactin, negative symptoms, 41:191  
 prolactin, neuroleptics, 41:191  
 prolactin, schizophrenia, 41:191  
 prolactin, side effects, 41:191  
 prolactin, substance abuse, 43:77  
 schizophrenia, abnormal-movement disorders, 41:191  
 schizophrenia, dyskinesia, 41:191  
 schizophrenia, haloperidol, 41:191  
 schizophrenia, negative symptoms, 41:191  
 schizophrenia, neuroleptics, 41:191  
 schizophrenia, prolactin, 41:191  
 schizophrenia, side effects, 41:191  
 side effects, haloperidol, 41:191  
 side effects, negative symptoms, 41:191  
 side effects, neuroleptics, 41:191  
 side effects, prolactin, 41:191  
 side effects, schizophrenia, 41:191  
 substance abuse, abstinence, 43:77  
 substance abuse, carbidopa treatment, 43:77  
 substance abuse, cocaine, 43:77  
 substance abuse, growth hormone, 43:77  
 substance abuse, MHPG, 43:77  
 substance abuse, prolactin, 43:77  
 Tourette's syndrome, neuropsychological tasks, 43:277  
 Tourette's syndrome, trace amines, 43:277  
 trace amines, neuropsychological tasks, 43:277  
 trace amines, Tourette's syndrome, 43:277

**Imipramine**  
 ACTH, antidepressants, 41:45  
 ACTH, cortisol, 41:45

**Imipramine** continued  
 ACTH, glucose, 41:45  
 ACTH, insulin tolerance test, 41:45  
 ACTH, normal subjects, 41:45  
 adenosyl-L-methionine, affective disorder, 44:257  
 adenosyl-L-methionine, antidepressants, 44:257  
 affective disorder, adenosyl-L-methionine, 44:257  
 affective disorder, antidepressants, 44:257  
 antidepressants, ACTH, 41:45  
 antidepressants, adenosyl-L-methionine, 44:257  
 antidepressants, affective disorder, 44:257  
 antidepressants, cortisol, 41:45  
 antidepressants, glucose, 41:45  
 antidepressants, insulin tolerance test, 41:45  
 antidepressants, normal subjects, 41:45  
 cortisol, ACTH, 41:45  
 cortisol, antidepressants, 41:45  
 cortisol, glucose, 41:45  
 cortisol, insulin tolerance test, 41:45  
 cortisol, normal subjects, 41:45  
 glucose, ACTH, 41:45  
 glucose, antidepressants, 41:45  
 glucose, cortisol, 41:45  
 glucose, insulin tolerance test, 41:45  
 glucose, normal subjects, 41:45  
 insulin tolerance test, ACTH, 41:45  
 insulin tolerance test, antidepressants, 41:45  
 insulin tolerance test, cortisol, 41:45  
 insulin tolerance test, glucose, 41:45  
 insulin tolerance test, normal subjects, 41:45  
 normal subjects, ACTH, 41:45  
 normal subjects, antidepressants, 41:45  
 normal subjects, cortisol, 41:45  
 normal subjects, glucose, 41:45  
 normal subjects, insulin tolerance test, 41:45  
 obsessive-compulsive disorder, platelet imipramine binding, 42:41  
 obsessive-compulsive disorder, serotonin, 42:41  
 obsessive-compulsive disorder, sulfotransferase in platelets, 42:41  
 platelet imipramine binding, obsessive-compulsive disorder, 42:41  
 platelet imipramine binding, serotonin, 42:41  
 platelet imipramine binding, sulfotransferase in platelets, 42:41  
 serotonin, obsessive-compulsive disorder, 42:41  
 serotonin, platelet imipramine binding, 42:41  
 serotonin, sulfotransferase in platelets, 42:41  
 sulfotransferase in platelets, obsessive-compulsive disorder, 42:41

**Imipramine** continued

sulfotransferase in platelets, platelet imipramine binding, 42:41  
 sulfotransferase in platelets, serotonin, 42:41

**Indole-3-acetic acid**

5-HIAA, obsessive-compulsive disorder, 41:267  
 5-HIAA, serotonin, 41:267  
 5-HIAA, Tourette's syndrome, 41:267  
 5-HIAA, tryptamine, 41:267  
 obsessive-compulsive disorder, 5-HIAA, 41:267  
 obsessive-compulsive disorder, serotonin, 41:267  
 obsessive-compulsive disorder, Tourette's syndrome, 41:267  
 obsessive-compulsive disorder, tryptamine, 41:267  
 serotonin, 5-HIAA, 41:267  
 serotonin, obsessive-compulsive disorder, 41:267  
 serotonin, Tourette's syndrome, 41:267  
 serotonin, tryptamine, 41:267  
 Tourette's syndrome, 5-HIAA, 41:267  
 Tourette's syndrome, obsessive-compulsive disorder, 41:267  
 Tourette's syndrome, serotonin, 41:267  
 Tourette's syndrome, tryptamine, 41:267  
 tryptamine, 5-HIAA, 41:267  
 tryptamine, obsessive-compulsive disorder, 41:267  
 tryptamine, serotonin, 41:267  
 tryptamine, Tourette's syndrome, 41:267

**Insulin tolerance test**

ACTH, antidepressants, 41:45  
 ACTH, cortisol, 41:45  
 ACTH, glucose, 41:45  
 ACTH, imipramine, 41:45  
 ACTH, normal subjects, 41:45  
 antidepressants, ACTH, 41:45  
 antidepressants, cortisol, 41:45  
 antidepressants, glucose, 41:45  
 antidepressants, normal subjects, 41:45  
 cortisol, ACTH, 41:45  
 cortisol, antidepressants, 41:45  
 cortisol, glucose, 41:45  
 cortisol, imipramine, 41:45  
 cortisol, normal subjects, 41:45  
 glucose, ACTH, 41:45  
 glucose, antidepressants, 41:45  
 glucose, cortisol, 41:45  
 glucose, imipramine, 41:45  
 glucose, normal subjects, 41:45  
 imipramine, ACTH, 41:45  
 imipramine, cortisol, 41:45

**Insulin tolerance test** continued

imipramine, glucose, 41:45  
 imipramine, normal subjects, 41:45  
 normal subjects, ACTH, 41:45  
 normal subjects, antidepressants, 41:45  
 normal subjects, cortisol, 41:45  
 normal subjects, glucose, 41:45  
 normal subjects, imipramine, 41:45

**Intelligence**

eye movements, hand preference, 41:115  
 eye movements, laterality, 41:115  
 eye movements, neuropsychological tests, 41:115  
 eye movements, normal men, 41:115  
 eye movements, schizotypy, 41:115  
 hand preference, eye movements, 41:115  
 hand preference, laterality, 41:115  
 hand preference, neuropsychological tests, 41:115  
 hand preference, normal men, 41:115  
 hand preference, schizotypy, 41:115  
 laterality, eye movements, 41:115  
 laterality, hand preference, 41:115  
 laterality, neuropsychological tests, 41:115  
 laterality, normal men, 41:115  
 laterality, schizotypy, 41:115  
 neuropsychological tests, eye movements, 41:115  
 neuropsychological tests, hand preference, 41:115  
 neuropsychological tests, laterality, 41:115  
 neuropsychological tests, normal men, 41:115  
 neuropsychological tests, schizotypy, 41:115  
 normal men, eye movements, 41:115  
 normal men, hand preference, 41:115  
 normal men, laterality, 41:115  
 normal men, neuropsychological tests, 41:115  
 normal men, schizotypy, 41:115  
 schizotypy, eye movements, 41:115  
 schizotypy, hand preference, 41:115  
 schizotypy, laterality, 41:115  
 schizotypy, neuropsychological tests, 41:115  
 schizotypy, normal men, 41:115

**Laterality**

attention, negative symptoms, 43:87  
 attention, reaction time, 43:87  
 attention, schizophrenia, 43:87  
 emotion, facial affective discrimination, 42:231  
 emotion, sex differences, 42:231  
 eye movements, hand preference, 41:115  
 eye movements, intelligence, 41:115  
 eye movements, neuropsychological tests, 41:115  
 eye movements, normal men, 41:115

**Laterality** continued

eye movements, schizotypy, 41:115  
 facial affective discrimination, emotion, 42:231  
 facial affective discrimination, sex differences, 42:231  
 hand preference, eye movements, 41:115  
 hand preference, intelligence, 41:115  
 hand preference, neuropsychological tests, 41:115  
 hand preference, normal men, 41:115  
 hand preference, schizotypy, 41:115  
 intelligence, eye movements, 41:115  
 intelligence, hand preference, 41:115  
 intelligence, neuropsychological tests, 41:115  
 intelligence, normal men, 41:115  
 intelligence, schizotypy, 41:115  
 negative symptoms, attention, 43:87  
 negative symptoms, reaction time, 43:87  
 negative symptoms, schizophrenia, 43:87  
 neuropsychological tests, eye movements, 41:115  
 neuropsychological tests, hand preference, 41:115  
 neuropsychological tests, intelligence, 41:115  
 neuropsychological tests, normal men, 41:115  
 neuropsychological tests, schizotypy, 41:115  
 normal men, eye movements, 41:115  
 normal men, hand preference, 41:115  
 normal men, intelligence, 41:115  
 normal men, neuropsychological tests, 41:115  
 normal men, schizotypy, 41:115  
 reaction time, attention, 43:87  
 reaction time, negative symptoms, 43:87  
 reaction time, schizophrenia, 43:87  
 schizophrenia, attention, 43:87  
 schizophrenia, negative symptoms, 43:87  
 schizophrenia, reaction time, 43:87  
 schizotypy, eye movements, 41:115  
 schizotypy, hand preference, 41:115  
 schizotypy, intelligence, 41:115  
 schizotypy, neuropsychological tests, 41:115  
 schizotypy, normal men, 41:115  
 sex differences, emotion, 42:231  
 sex differences, facial affective discrimination, 42:231

**Neuroleptics**

abnormal-movement disorders, homovanillic acid, 41:191  
 abnormal-movement disorders, negative symptoms, 41:191  
 abnormal-movement disorders, prolactin, 41:191  
 abnormal-movement disorders, schizophrenia, 41:191  
**Neuroleptics** continued  
 bioassay vs. radioimmunoassay, prolactin, 41:249  
 bioassay vs. radioimmunoassay, schizophrenia, 41:249  
 ceruleotide, schizophrenia, 43:129  
 ceruleotide, side effects, 43:129  
 ceruleotide, tardive dyskinesia, 43:129  
 clozapine, eye movements, 41:25  
 clozapine, saccadic intrusions, 41:25  
 clozapine, schizophrenia, 41:25  
 dyskinesia, haloperidol, 41:191  
 dyskinesia, homovanillic acid, 41:191  
 dyskinesia, negative symptoms, 41:191  
 dyskinesia, prolactin, 41:191  
 dyskinesia, schizophrenia, 41:191  
 dyskinesia, side effects, 41:191  
 EEG, haloperidol, 42:129  
 EEG, schizophrenia, 42:129  
 EEG, treatment response, 42:129  
 electrodermal activity, positive symptoms, 42:145  
 electrodermal activity, schizophrenia, 42:145  
 eye movements, clozapine, 41:25  
 eye movements, saccadic intrusions, 41:25  
 eye movements, schizophrenia, 41:25  
 haloperidol, abnormal-movement disorders, 41:191  
 haloperidol, dyskinesia, 41:191  
 haloperidol, EEG, 42:129  
 haloperidol, homovanillic acid, 41:191  
 haloperidol, negative symptoms, 41:191  
 haloperidol, prolactin, 41:191  
 haloperidol, pupillometry, 43:287  
 haloperidol, relapse, 43:287  
 haloperidol, schizophrenia, 41:191, 42:129, 43:287  
 haloperidol, side effects, 41:191  
 haloperidol, treatment response, 42:129  
 homovanillic acid, abnormal-movement disorders, 41:191  
 homovanillic acid, dyskinesia, 41:191  
 homovanillic acid, haloperidol, 41:191  
 homovanillic acid, negative symptoms, 41:191  
 homovanillic acid, prolactin, 41:191  
 homovanillic acid, schizophrenia, 41:191  
 homovanillic acid, side effects, 41:191  
 negative symptoms, abnormal-movement disorders, 41:191  
 negative symptoms, dyskinesia, 41:191  
 negative symptoms, haloperidol, 41:191  
 negative symptoms, homovanillic acid, 41:191  
 negative symptoms, prolactin, 41:191  
 negative symptoms, schizophrenia, 41:191

**Neuroleptics continued**

negative symptoms, side effects, 41:191  
 neuroleptic malignant syndrome,  
 schizophrenia, 44:251  
 neuroleptic malignant syndrome, temperature,  
 44:251  
 Parkinsonism, schizophrenia, 41:9  
 Parkinsonism, side effects, 41:9  
 Parkinsonism, terguride, 41:9  
 perphenazine, psychosis, 41:147  
 perphenazine, symptom response, 41:147  
 positive symptoms, electrodermal activity, 42:145  
 positive symptoms, schizophrenia, 42:145  
 prolactin, abnormal-movement disorders,  
 41:191  
 prolactin, bioassay vs. radioimmunoassay,  
 41:249  
 prolactin, dyskinesia, 41:191  
 prolactin, haloperidol, 41:191  
 prolactin, homovanillic acid, 41:191  
 prolactin, negative symptoms, 41:191  
 prolactin, schizophrenia, 41:191, 41:249  
 prolactin, side effects, 41:191  
 psychosis, perphenazine, 41:147  
 psychosis, symptom response, 41:147  
 pupillometry, haloperidol, 43:287  
 pupillometry, relapse, 43:287  
 pupillometry, schizophrenia, 43:287  
 relapse, haloperidol, 43:287  
 relapse, pupillometry, 43:287  
 relapse, schizophrenia, 43:287  
 saccadic intrusions, clozapine, 41:25  
 saccadic intrusions, eye movements, 41:25  
 saccadic intrusions, schizophrenia, 41:25  
 schizophrenia, abnormal-movement disorders,  
 41:191  
 schizophrenia, bioassay vs radioimmunoassay,  
 41:249  
 schizophrenia, ceruleotide, 43:129  
 schizophrenia, clozapine, 41:25  
 schizophrenia, dyskinesia, 41:191  
 schizophrenia, EEG, 42:129  
 schizophrenia, electrodermal activity, 42:145  
 schizophrenia, eye movements, 41:25  
 schizophrenia, haloperidol, 41:191, 42:129,  
 43:287  
 schizophrenia, homovanillic acid, 41:191  
 schizophrenia, negative symptoms, 41:191  
 schizophrenia, neuroleptic malignant  
 syndrome, 44:251  
 schizophrenia, Parkinsonism, 41:9  
 schizophrenia, positive symptoms, 42:145  
 schizophrenia, prolactin, 41:191, 41:249  
 schizophrenia, pupillometry, 43:287

**Neuroleptics continued**

schizophrenia, relapse, 43:287  
 schizophrenia, saccadic intrusions, 41:25  
 schizophrenia, side effects, 41:9, 41:191  
 schizophrenia, side effects, 43:129  
 schizophrenia, tardive dyskinesia, 43:129  
 schizophrenia, temperature, 44:251  
 schizophrenia, terguride, 41:9  
 schizophrenia, treatment response, 42:129  
 side effects, ceruleotide, 43:129  
 side effects, dyskinesia, 41:191  
 side effects, haloperidol, 41:191  
 side effects, homovanillic acid, 41:191  
 side effects, negative symptoms, 41:191  
 side effects, prolactin, 41:191  
 side effects, schizophrenia, 41:9, 41:191,  
 43:129  
 side effects, terguride, 41:9  
 symptom response, perphenazine, 41:147  
 symptom response, psychosis, 41:147  
 tardive dyskinesia, ceruleotide, 43:129  
 tardive dyskinesia, schizophrenia, 43:129  
 temperature, neuroleptic malignant syndrome,  
 44:251  
 temperature, neuroleptics, 44:251  
 temperature, schizophrenia, 44:251  
 terguride, Parkinsonism, 41:9  
 terguride, schizophrenia, 41:9  
 terguride, side effects, 41:9  
 treatment response, EEG, 42:129  
 treatment response, haloperidol, 42:129  
 treatment response, schizophrenia, 42:129  
**Neuropsychological tests**  
 Alzheimer's disease, diagnosis, 44:93  
 attention, dramatic personality cluster, 42:283  
 attention, memory, 42:283  
 attention, personality disorder, 42:283  
 catecholamines in urine, memory, 43:277  
 catecholamines in urine, MHPG, 43:277  
 catecholamines in urine, serotonin, 43:277  
 catecholamines in urine, Tourette's syndrome,  
 43:277  
 color naming, frontal lobe, 41:137  
 color naming, schizophrenia, 41:137  
 color naming, Stroop task, 41:137  
 diagnosis, Alzheimer's disease, 44:93  
 dramatic personality cluster, attention, 42:283  
 dramatic personality cluster, memory, 42:283  
 eye movements, hand preference, 41:115  
 eye movements, intelligence, 41:115  
 eye movements, laterality, 41:115  
 eye movements, normal men, 41:115  
 eye movements, schizotypy, 41:115  
 frontal lobe, color naming, 41:137

**Neuropsychological tests** continued  
 frontal lobe, schizophrenia, 41:137  
 frontal lobe, Stroop task, 41:137  
 hand preference, eye movements, 41:115  
 hand preference, intelligence, 41:115  
 hand preference, laterality, 41:115  
 hand preference, normal men, 41:115  
 hand preference, schizotypy, 41:115  
 HIV, substance abuse, 41:163  
 homovanillic acid, Tourette's syndrome, 43:277  
 homovanillic acid, trace amines, 43:277  
 intelligence, eye movements, 41:115  
 intelligence, hand preference, 41:115  
 intelligence, laterality, 41:115  
 intelligence, normal men, 41:115  
 intelligence, schizotypy, 41:115  
 laterality, eye movements, 41:115  
 laterality, hand preference, 41:115  
 laterality, intelligence, 41:115  
 laterality, normal men, 41:115  
 laterality, schizotypy, 41:115  
 memory, attention, 42:283  
 memory, catecholamines in urine, 43:277  
 memory, dramatic personality cluster, 42:283  
 memory, MHPG, 43:277  
 memory, personality disorder, 42:283  
 memory, serotonin, 43:277  
 memory, Tourette's syndrome, 43:277  
 MHPG, catecholamines in urine, 43:277  
 MHPG, memory, 43:277  
 MHPG, serotonin, 43:277  
 MHPG, Tourette's syndrome, 43:277  
 normal men, eye movements, 41:115  
 normal men, hand preference, 41:115  
 normal men, intelligence, 41:115  
 normal men, laterality, 41:115  
 normal men, schizotypy, 41:115  
 personality disorder, attention, 42:283  
 personality disorder, memory, 42:283  
 rehabilitation, schizophrenia, 43:223  
 rehabilitation, social skills, 43:223  
 schizophrenia, color naming, 41:137  
 schizophrenia, frontal lobe, 41:137  
 schizophrenia, rehabilitation, 43:223  
 schizophrenia, social skills, 43:223  
 schizophrenia, Stroop task, 41:137  
 schizotypy, eye movements, 41:115  
 schizotypy, hand preference, 41:115  
 schizotypy, intelligence, 41:115  
 schizotypy, laterality, 41:115  
 schizotypy, normal men, 41:115  
 serotonin, catecholamines in urine, 43:277  
 serotonin, memory, 43:277

**Neuropsychological tests** continued  
 serotonin, MHPG, 43:277  
 serotonin, Tourette's syndrome, 43:277  
 social skills, rehabilitation, 43:223  
 social skills, schizophrenia, 43:223  
 Stroop task, color naming, 41:137  
 Stroop task, frontal lobe, 41:137  
 Stroop task, schizophrenia, 41:137  
 substance abuse, HIV, 41:163  
 Tourette's syndrome, catecholamines in urine, 43:277  
 Tourette's syndrome, homovanillic acid, 43:277  
 Tourette's syndrome, memory, 43:277  
 Tourette's syndrome, MHPG, 43:277  
 Tourette's syndrome, serotonin, 43:277  
 Tourette's syndrome, trace amines, 43:277  
 trace amines, homovanillic acid, 43:277  
 trace amines, Tourette's syndrome, 43:277  
**Norepinephrine**  
 affective disorder, blood pressure, 43:199  
 affective disorder, clonidine, 43:199  
 affective disorder, cortisol, 43:31, 43:65  
 affective disorder, desipramine, 43:65  
 affective disorder, dopamine, 43:31  
 affective disorder, epinephrine in urine, 43:31  
 affective disorder, heart rate, 43:199  
 affective disorder, MCPP, 43:65  
 affective disorder, MHPG, 43:199  
 affective disorder, panic disorder, 43:65  
 affective disorder, serotonin, 43:65  
 affective disorder, suicide, 43:31  
 blood pressure, affective disorder, 43:199  
 blood pressure, clonidine, 43:199  
 blood pressure, heart rate, 43:199  
 blood pressure, MHPG, 43:199  
 clonidine, affective disorder, 43:199  
 clonidine, blood pressure, 43:199  
 clonidine, heart rate, 43:199  
 clonidine, MHPG, 43:199  
 cortisol, affective disorder, 43:31, 43:65  
 cortisol, desipramine, 43:65  
 cortisol, dopamine, 43:31  
 cortisol, epinephrine in urine, 43:31  
 cortisol, MCPP, 43:65  
 cortisol, panic disorder, 43:65  
 cortisol, serotonin, 43:65  
 cortisol, suicide, 43:31  
 desipramine, affective disorder, 43:65  
 desipramine, cortisol, 43:65  
 desipramine, MCPP, 43:65  
 desipramine, panic disorder, 43:65  
 desipramine, serotonin, 43:65  
 diazepam, heart rate, 41:89

**Norepinephrine** continued

- diazepam, normal men, 41:89
- diazepam, vagal tone, 41:89
- dopamine, affective disorder, 43:31
- dopamine, cortisol, 43:31
- dopamine, epinephrine in urine, 43:31
- dopamine, suicide, 43:31
- epinephrine in urine, affective disorder, 43:31
- epinephrine in urine, cortisol, 43:31
- epinephrine in urine, dopamine, 43:31
- epinephrine in urine, suicide, 43:31
- evoked potentials, MHPG, 44:21
- evoked potentials, schizophrenia, 44:21
- evoked potentials, sensory gating, 44:21
- heart rate, affective disorder, 43:199
- heart rate, blood pressure, 43:199
- heart rate, clonidine, 43:199
- heart rate, diazepam, 41:89
- heart rate, MHPG, 43:199
- heart rate, normal men, 41:89
- heart rate, vagal tone, 41:89
- MCPP, affective disorder, 43:65
- MCPP, cortisol, 43:65
- MCPP, desipramine, 43:65
- MCPP, panic disorder, 43:65
- MCPP, serotonin, 43:65
- MHPG, affective disorder, 43:199
- MHPG, blood pressure, 43:199
- MHPG, clonidine, 43:199
- MHPG, evoked potentials, 44:21
- MHPG, heart rate, 43:199
- MHPG, schizophrenia, 44:21
- MHPG, sensory gating, 44:21
- normal men, diazepam, 41:89
- normal men, heart rate, 41:89
- normal men, vagal tone, 41:89
- panic disorder, affective disorder, 43:65
- panic disorder, cortisol, 43:65
- panic disorder, desipramine, 43:65
- panic disorder, MCPP, 43:65
- panic disorder, serotonin, 43:65
- schizophrenia, evoked potentials, 44:21
- schizophrenia, MHPG, 44:21
- schizophrenia, sensory gating, 44:21
- sensory gating, evoked potentials, 44:21
- sensory gating, MHPG, 44:21
- sensory gating, schizophrenia, 44:21
- serotonin, affective disorder, 43:65
- serotonin, cortisol, 43:65
- serotonin, desipramine, 43:65
- serotonin, MCPP, 43:65
- serotonin, panic disorder, 43:65
- suicide, affective disorder, 43:31
- suicide, cortisol, 43:31

**Norepinephrine** continued

- suicide, dopamine, 43:31
- suicide, epinephrine in urine, 43:31
- vagal tone, diazepam, 41:89
- vagal tone, heart rate, 41:89
- vagal tone, normal men, 41:89

**Obsessive-compulsive disorder**

- affective disorder, amino acids in plasma, 44:91
- affective disorder, comorbidity, 42:111
- affective disorder, genetics, 42:111
- affective disorder, tryptophan, 44:91
- amino acids in plasma, affective disorder, 44:91
- amino acids in plasma, tryptophan, 44:91
- anxiety, depressed mood, 42:267
- anxiety, dystonia, 42:267
- anxiety, torticollis, 42:267
- comorbidity, affective disorder, 42:111
- comorbidity, genetics, 42:111
- comorbidity, panic disorder, 42:171
- cortisol, melatonin, 44:217
- depressed mood, anxiety, 42:267
- depressed mood, dystonia, 42:267
- depressed mood, torticollis, 42:267
- dystonia, anxiety, 42:267
- dystonia, depressed mood, 42:267
- dystonia, torticollis, 42:267
- eyemovements, smooth pursuit, 42:1
- fenfluramine, homovanillic acid, 42:185
- fenfluramine, prolactin, 42:81
- fenfluramine, serotonin, 42:81
- fenfluramine, sex differences, 42:81
- genetics, affective disorder, 42:111
- genetics, comorbidity, 42:111
- 5-HIAA, indole-3-acetic acid, 41:267
- 5-HIAA, serotonin, 41:267
- 5-HIAA, Tourette's syndrome, 41:267
- 5-HIAA, tryptamine, 41:267
- homovanillic acid, fenfluramine, 42:185
- imipramine, platelet imipramine binding, 42:41
- imipramine, serotonin, 42:41
- imipramine, sulfotransferase in platelets, 42:41
- indole-3-acetic acid, 5-HIAA, 41:267
- indole-3-acetic acid, serotonin, 41:267
- indole-3-acetic acid, Tourette's syndrome, 41:267
- indole-3-acetic acid, tryptamine, 41:267
- melatonin, cortisol, 44:217
- panic disorder, comorbidity, 42:171
- platelet imipramine binding, serotonin, 42:41
- platelet imipramine binding, sulfotransferase in platelets, 42:41

**Obsessive-compulsive disorder** continued  
 prolactin, fenfluramine, 42:81  
 prolactin, serotonin, 42:81  
 prolactin, sex differences, 42:81  
 reliability and validity, Symptom Checklist-90, 41:37  
 serotonin, fenfluramine, 42:81  
 serotonin, 5-HIAA, 41:267  
 serotonin, imipramine, 42:41  
 serotonin, indole-3-acetic acid, 41:267  
 serotonin, platelet imipramine binding, 42:41  
 serotonin, prolactin, 42:81  
 serotonin, sex differences, 42:81  
 serotonin, sulfotransferase in platelets, 42:41  
 serotonin, Tourette's syndrome, 41:267  
 serotonin, tryptamine, 41:267  
 sex differences, fenfluramine, 42:81  
 sex differences, prolactin, 42:81  
 sex differences, serotonin, 42:81  
 smooth pursuit, eye movements, 42:1  
 sulfotransferase in platelets, imipramine, 42:41  
 sulfotransferase in platelets, platelet imipramine binding, 42:41  
 sulfotransferase in platelets, serotonin, 42:41  
 Symptom Checklist-90, reliability and validity, 41:37  
 torticollis, anxiety, 42:267  
 torticollis, depressed mood, 42:267  
 torticollis, dystonia, 42:267  
 Tourette's syndrome, 5-HIAA, 41:267  
 Tourette's syndrome, indole-3-acetic acid, 41:267  
 Tourette's syndrome, serotonin, 41:267  
 Tourette's syndrome, tryptamine, 41:267  
 tryptamine, 5-HIAA, 41:267  
 tryptamine, indole-3-acetic acid, 41:267  
 tryptamine, serotonin, 41:267  
 tryptamine, Tourette's syndrome, 41:267  
 tryptophan, affective disorder, 44:91  
 tryptophan, amino acids in plasma, 44:91  
**Parkinsonism**  
 neuroleptics, schizophrenia, 41:9  
 neuroleptics, side effects, 41:9  
 neuroleptics, terguride, 41:9  
 schizophrenia, neuroleptics, 41:9  
 schizophrenia, side effects, 41:9  
 schizophrenia, terguride, 41:9  
 side effects, neuroleptics, 41:9  
 side effects, schizophrenia, 41:9  
 side effects, terguride, 41:9  
 terguride, neuroleptics, 41:9  
 terguride, schizophrenia, 41:9

**Perphenazine**  
 neuroleptics, psychosis, 41:147  
 neuroleptics, symptom response, 41:147  
 psychosis, neuroleptics, 41:147  
 psychosis, symptom response, 41:147  
 symptom response, neuroleptics, 41:147  
 symptom response, psychosis, 41:147  
**Prolactin**  
 abnormal-movement disorders, dyskinesia, 41:191  
 abnormal-movement disorders, haloperidol, 41:191  
 abnormal-movement disorders, homovanillic acid, 41:191  
 abnormal-movement disorders, negative symptoms, 41:191  
 abnormal-movement disorders, neuroleptics, 41:191  
 abnormal-movement disorders, schizophrenia, 41:191  
 abnormal-movement disorders, side effects, 41:191  
 abstinence, carbidopa treatment, 43:77  
 abstinence, cocaine, 43:77  
 abstinence, growth hormone, 43:77  
 abstinence, homovanillic acid, 43:77  
 abstinence, MHPG, 43:77  
 abstinence, substance abuse, 43:77  
 ACTH, MCPP, 43:1  
 ACTH, schizophrenia, 43:1  
 ACTH, serotonin, 43:1  
 ACTH, temperature of body, 43:1  
 affective disorder, cortisol, 43:137  
 affective disorder, fenfluramine, 43:137  
 affective disorder, melancholia, 43:137  
 affective disorder, serotonin, 43:137  
 aggression, childhood disorders, 43:263  
 aggression, cortisol, 43:263  
 aggression, disruptive behavior disorder, 43:263  
 aggression, fenfluramine, 43:263  
 aggression, serotonin, 43:263  
 alcoholism, thyroxine, 43:121  
 alcoholism, TRH, 43:121  
 alcoholism, triiodothyronine, 43:121  
 alcoholism, TSH, 43:121  
 attention deficit disorder, cortisol, 42:65  
 attention deficit disorder, fenfluramine challenge, 42:65  
 bioassay vs. radioimmunoassay, neuroleptics, 41:249  
 bioassay vs. radioimmunoassay, schizophrenia, 41:249  
 carbidopa treatment, abstinence, 43:77

**Prolactin continued**

carbidopa treatment, cocaine, 43:77  
 carbidopa treatment, growth hormone, 43:77  
 carbidopa treatment, homovanillic acid, 43:77  
 carbidopa treatment, MHPG, 43:77  
 carbidopa treatment, substance abuse, 43:77  
 childhood disorders, aggression, 43:263  
 childhood disorders, attention deficit disorder, 42:65  
 childhood disorders, cortisol, 42:65  
 childhood disorders, cortisol, 43:263  
 childhood disorders, disruptive behavior disorder, 42:65, 43:263  
 childhood disorders, fenfluramine, 43:263  
 childhood disorders, fenfluramine challenge, 42:65  
 childhood disorders, serotonin, 43:263  
 circadian rhythms, cortisol, 43:161  
 circadian rhythms, melatonin, 43:161  
 circadian rhythms, platelet serotonin uptake, 43:161  
 circadian rhythms, serotonin, 43:161  
 cocaine, abstinence, 43:77  
 cocaine, carbidopa treatment, 43:77  
 cocaine, growth hormone, 43:77  
 cocaine, homovanillic acid, 43:77  
 cocaine, MHPG, 43:77  
 cocaine, substance abuse, 43:77  
 cortisol, affective disorder, 43:137  
 cortisol, aggression, 43:263  
 cortisol, attention deficit disorder, 42:65  
 cortisol, childhood disorders, 42:65, 43:263  
 cortisol, circadian rhythms, 43:161  
 cortisol, disruptive behavior disorder, 42:65, 43:263  
 cortisol, fenfluramine, 43:137, 43:263  
 cortisol, fenfluramine challenge, 42:65  
 cortisol, melancholia, 43:137  
 cortisol, melatonin, 43:161  
 cortisol, platelet serotonin uptake, 43:161  
 cortisol, serotonin, 43:137, 43:161, 43:263  
 disruptive behavior disorder, aggression, 43:263  
 disruptive behavior disorder, childhood disorders, 43:263  
 disruptive behavior disorder, cortisol, 42:65, 43:263  
 disruptive behavior disorder, fenfluramine, 42:65, 43:263  
 disruptive behavior disorder, serotonin, 43:263  
 domperidone, dopamine, 42:159  
 domperidone, growth hormone, 42:159  
 domperidone, schizophrenia, 42:159

**Prolactin continued**

dopamine, domperidone, 42:159  
 dopamine, growth hormone, 42:159  
 dopamine, schizophrenia, 42:159  
 dyskinesia, haloperidol, 41:191  
 dyskinesia, homovanillic acid, 41:191  
 dyskinesia, negative symptoms, 41:191  
 dyskinesia, neuroleptics, 41:191  
 dyskinesia, schizophrenia, 41:191  
 fenfluramine, affective disorder, 43:137  
 fenfluramine, aggression, 43:263  
 fenfluramine challenge, attention deficit disorder, 42:65  
 fenfluramine challenge, childhood disorders, 42:65  
 fenfluramine challenge, cortisol, 42:65  
 fenfluramine challenge, disruptive behavior disorder, 42:65  
 fenfluramine, childhood disorders, 43:263  
 fenfluramine, cortisol, 43:137, 43:263  
 fenfluramine, disruptive behavior disorder, 43:263  
 fenfluramine, melancholia, 43:137  
 fenfluramine, obsessive-compulsive disorder, 42:81  
 fenfluramine, serotonin, 42:81, 43:137, 43:263  
 fenfluramine, sex differences, 42:81  
 growth hormone, abstinence, 43:77  
 growth hormone, carbidopa treatment, 43:77  
 growth hormone, cocaine, 43:77  
 growth hormone, domperidone, 42:159  
 growth hormone, dopamine, 42:159  
 growth hormone, homovanillic acid, 43:77  
 growth hormone, MHPG, 43:77  
 growth hormone, schizophrenia, 42:159  
 growth hormone, substance abuse, 43:77  
 haloperidol, abnormal-movement disorders, 41:191  
 haloperidol, dyskinesia, 41:191  
 haloperidol, homovanillic acid, 41:191  
 haloperidol, negative symptoms, 41:191  
 haloperidol, schizophrenia, 41:191  
 haloperidol, side effects, 41:191  
 homovanillic acid, abnormal-movement disorders, 41:191  
 homovanillic acid, abstinence, 43:77  
 homovanillic acid, carbidopa treatment, 43:77  
 homovanillic acid, cocaine, 43:77  
 homovanillic acid, dyskinesia, 41:191  
 homovanillic acid, growth hormone, 43:77  
 homovanillic acid, haloperidol, 41:191  
 homovanillic acid, MHPG, 43:77  
 homovanillic acid, negative symptoms, 41:191  
 homovanillic acid, neuroleptics, 41:191

**Prolactin** continued

homovanillic acid, schizophrenia, 41:191  
 homovanillic acid, side effects, 41:191  
 homovanillic acid, substance abuse, 43:77  
 MCPP, ACTH, 43:1  
 MCPP, schizophrenia, 43:1  
 MCPP, serotonin, 43:1  
 MCPP, temperature of body, 43:1  
 melancholia, affective disorder, 43:137  
 melancholia, cortisol, 43:137  
 melancholia, fenfluramine, 43:137  
 melancholia, serotonin, 43:137  
 melatonin, circadian rhythms, 43:161  
 melatonin, cortisol, 43:161  
 melatonin, platelet serotonin uptake, 43:161  
 melatonin, serotonin, 43:161  
 MHPG, abstinence, 43:77  
 MHPG, carbidopa treatment, 43:77  
 MHPG, cocaine, 43:77  
 MHPG, growth hormone, 43:77  
 MHPG, homovanillic acid, 43:77  
 MHPG, substance abuse, 43:77  
 negative symptoms, abnormal-movement disorders, 41:191  
 negative symptoms, dyskinesia, 41:191  
 negative symptoms, haloperidol, 41:191  
 negative symptoms, homovanillic acid, 41:191  
 negative symptoms, neuroleptics, 41:191  
 negative symptoms, schizophrenia, 41:191  
 negative symptoms, side effects, 41:191  
 neuroleptics, abnormal-movement disorders, 41:191  
 neuroleptics, bioassay vs. radioimmunoassay, 41:249  
 neuroleptics, dyskinesia, 41:191  
 neuroleptics, haloperidol, 41:191  
 neuroleptics, homovanillic acid, 41:191  
 neuroleptics, negative symptoms, 41:191  
 neuroleptics, schizophrenia, 41:191, 41:249  
 neuroleptics, side effects, 41:191  
 obsessive-compulsive disorder, fenfluramine, 42:81  
 obsessive-compulsive disorder, serotonin, 42:81  
 obsessive-compulsive disorder, sex differences, 42:81  
 platelet serotonin uptake, circadian rhythms, 43:161  
 platelet serotonin uptake, cortisol, 43:161  
 platelet serotonin uptake, melatonin, 43:161  
 schizophrenia, abnormal-movement disorders, 41:191  
 schizophrenia, ACTH, 43:1  
 schizophrenia, bioassay vs. radioimmunoassay, 41:249

**Prolactin** continued

schizophrenia, domperidone, 42:159  
 schizophrenia, dopamine, 42:159  
 schizophrenia, dyskinesia, 41:191  
 schizophrenia, growth hormone, 42:159  
 schizophrenia, haloperidol, 41:191  
 schizophrenia, homovanillic acid, 41:191  
 schizophrenia, MCPP, 43:1  
 schizophrenia, negative symptoms, 41:191  
 schizophrenia, neuroleptics, 41:191, 41:249  
 schizophrenia, serotonin, 43:1  
 schizophrenia, side effects, 41:191  
 schizophrenia, temperature of body, 43:1  
 serotonin, ACTH, 43:1  
 serotonin, affective disorder, 43:137  
 serotonin, aggression, 43:263  
 serotonin, childhood disorders, 43:263  
 serotonin, circadian rhythms, 43:161  
 serotonin, cortisol, 43:137, 43:161, 43:263  
 serotonin, disruptive behavior disorder, 43:263  
 serotonin, fenfluramine, 42:81, 43:137, 43:263  
 serotonin, MCPP, 43:1  
 serotonin, melancholia, 43:137  
 serotonin, melatonin, 43:161  
 serotonin, obsessive-compulsive disorder, 42:81  
 serotonin, platelet uptake, 43:161  
 serotonin, schizophrenia, 43:1  
 serotonin, sex differences, 42:81  
 serotonin, temperature of body, 43:1  
 sex differences, fenfluramine, 42:81  
 sex differences, obsessive-compulsive disorder, 42:81  
 sex differences, serotonin, 42:81  
 side effects, haloperidol, 41:191  
 side effects, homovanillic acid, 41:191  
 side effects, negative symptoms, 41:191  
 side effects, neuroleptics, 41:191  
 side effects, schizophrenia, 41:191  
 substance abuse, abstinence, 43:77  
 substance abuse, carbidopa treatment, 43:77  
 substance abuse, cocaine, 43:77  
 substance abuse, growth hormone, 43:77  
 substance abuse, homovanillic acid, 43:77  
 substance abuse, MHPG, 43:77  
 temperature of body, ACTH, 43:1  
 temperature of body, MCPP, 43:1  
 temperature of body, schizophrenia, 43:1  
 temperature of body, serotonin, 43:1  
 thyroxine, alcoholism, 43:121  
 thyroxine, TRH, 43:121  
 thyroxine, triiodothyronine, 43:121  
 thyroxine, TSH, 43:121  
 TRH, alcoholism, 43:121  
 TRH, thyroxine, 43:121

**Prolactin** continued

TRH, triiodothyronine, 43:121  
 TRH, TSH, 43:121  
 triiodothyronine, alcoholism, 43:121  
 triiodothyronine, thyroxine, 43:121  
 triiodothyronine, TRH, 43:121  
 triiodothyronine, TSH, 43:121  
 TSH, alcoholism, 43:121  
 TSH, thyroxine, 43:121  
 TSH, TRH, 43:121  
 TSH, triiodothyronine, 43:121

**Schizophrenia**

abnormal-movement disorders, haloperidol, 41:191  
 abnormal-movement disorders, homovanillic acid, 41:191  
 abnormal-movement disorders, negative symptoms, 41:191  
 abnormal-movement disorders, neuroleptics, 41:191  
 abnormal-movement disorders, prolactin, 41:191  
 ACTH, MCPP, 43:1  
 ACTH, prolactin, 43:1  
 ACTH, serotonin, 43:1  
 ACTH, temperature of body, 43:1  
 acute psychosis, symptom response, 41:147  
 affective disorder, cortisol, 44:1  
 affective disorder, eye movements, 43:93  
 affective disorder, monoamine oxidase, 44:1  
 affective disorder, paranoid subtype, 43:93  
 affective disorder, saccades, 43:93  
 age of onset, diagnostic subtypes, 41:107  
 age of onset, genetics, 41:107  
 age of onset, growth hormone at night, 41:155  
 age of onset, siblings, 41:107  
 attention, backward masking, 44:203  
 attention, genetics, 44:125  
 attention, high-risk study, 44:125  
 attention, laterality, 43:87  
 attention, negative symptoms, 43:87  
 attention, reaction time, 44:125, 43:87  
 backward masking, attention, 44:203  
 basal ganglia, GABAuptake site, 42:273  
 basal ganglia, glutamate uptake site, 42:273  
 basal ganglia, post-mortem brain, 42:273  
 bioassay vs. radioimmunoassay, neuroleptics, 41:249  
 bioassay vs. radioimmunoassay, prolactin, 41:249  
 calcium binding protein, chromogranin A, 42:53  
 calcium binding protein, polysomnography, 42:53

**Schizophrenia** continued

calcium binding protein, sleep, 42:53  
 cerebrospinal fluid, CRH, 43:13  
 cerebrospinal fluid, peptides, 43:13  
 cerebrospinal fluid, somatostatin, 43:13  
 cerebrospinal fluid, TRH, 43:13  
 ceruleotide, neuroleptics, 43:129  
 ceruleotide, side effects, 43:129  
 ceruleotide, tardive dyskinesia, 43:129  
 cholinesterase isozymes, polysomnography, 43:23  
 cholinesterase isozymes, sleep, 43:23  
 chromogranin A, calcium binding protein, 42:53  
 chromogranin A, polysomnography, 42:53  
 chromogranin A, sleep, 42:53  
 chromosome 5, genetics, 44:171  
 circadian rhythm, growth hormone, 41:155  
 circadian rhythm, sleep, 41:155  
 clozapine, electroencephalography, 44:107  
 clozapine, epileptic seizures, 44:107  
 clozapine, eyemovements, 41:25  
 clozapine, neuroleptics, 41:25  
 clozapine, saccadic intrusions, 41:25  
 color naming, frontal lobe, 41:137  
 color naming, neuropsychological tests, 41:137  
 color naming, Stroop task, 41:137  
 computed tomography, cortical atrophy, 44:55  
 computed tomography, negative symptoms, 44:55  
 computed tomography, subtype diagnosis, 42:209  
 computed tomography, symptomatology, 42:209  
 computed tomography, ventricle-brain ratio, 44:55  
 computed tomography, ventricular size, 42:209  
 content analysis, expressed emotion, 41:275  
 content analysis, family interview, 41:275  
 content analysis, relapse prediction, 41:275  
 cortical atrophy, computed tomography, 44:55  
 cortical atrophy, negative symptoms, 44:55  
 cortical atrophy, ventricle-brain ratio, 44:55  
 cortisol, affective disorder, 44:1  
 cortisol, monoamine oxidase, 44:1  
 CRH, cerebrospinal fluid, 43:13  
 CRH, peptides, 43:13  
 CRH, somatostatin, 43:13  
 CRH, TRH, 43:13  
 CSF, neuron-specific enolase, 43:187  
 delusional state, dopamine, 41:17  
 delusional state, platelets, 41:17  
 deprenyl, MAO inhibitors, 42:189  
 deprenyl, negative symptoms, 42:189

**Schizophrenia** continued

depression, mood state assessment, 42:199  
 depression, self vs. observer ratings, 42:199  
 diagnostic subtypes, age of onset, 41:107  
 diagnostic subtypes, genetics, 41:107  
 diagnostic subtypes, siblings, 41:107  
 domperidone, dopamine, 42:159  
 domperidone, growth hormone, 42:159  
 domperidone, prolactin, 42:159  
 dopamine, delusional state, 41:17  
 dopamine, domperidone, 42:159  
 dopamine, growth hormone, 42:159  
 dopamine, platelets, 41:17  
 dopamine, prolactin, 42:159  
 dyskinesia, haloperidol, 41:191  
 dyskinesia, homovanillic acid, 41:191  
 dyskinesia, negative symptoms, 41:191  
 dyskinesia, neuroleptics, 41:191  
 dyskinesia, prolactin, 41:191  
 EEG, haloperidol, 42:129  
 EEG, neuroleptics, 42:129  
 EEG, treatment response, 42:129  
 electrodermal activity, neuroleptics, 42:145  
 electrodermal activity, positive symptoms, 42:145  
 electroencephalography, clozapine, 44:107  
 electroencephalography, epileptic seizures, 44:107  
 emotion, facial affective discrimination, 42:253  
 emotion, symptom severity, 42:253  
 enolase, neurodegeneration, 43:187  
 entorhinal cortex, post-mortem study, 44:79  
 epileptic seizures, clozapine, 44:107  
 epileptic seizures, electroencephalography, 44:107  
 evoked potentials, eye movements, 41:227  
 evoked potentials, MHPG, 44:21  
 evoked potentials, norepinephrine, 44:21  
 evoked potentials, sensory gating, 44:21  
 expressed emotion, content analysis, 41:275  
 expressed emotion, family interview, 41:275  
 expressed emotion, relapse prediction, 41:275  
 eye movements, affective disorder, 43:93  
 eye movements, clozapine, 41:25  
 eye movements, evoked potentials, 41:227  
 eye movements, neuroleptics, 41:25  
 eye movements, paranoid subtype, 43:93  
 eye movements, saccades, 43:93  
 eye movements, saccadic intrusions, 41:25  
 facial affective discrimination, emotion, 42:253  
 facial affective discrimination, symptom severity, 42:253

**Schizophrenia** continued

factor analysis, negative symptoms, 44:153  
 factor analysis, thought disorder, 44:141  
 family interview, content analysis, 41:275  
 family interview, expressed emotion, 41:275  
 family interview, relapse prediction, 41:275  
 frontal lobe, color naming, 41:137  
 frontal lobe, neuropsychological tests, 41:137  
 frontal lobe, Stroop task, 41:137  
 GABA uptake site, basal ganglia, 42:273  
 GABA uptake site, glutamate uptake site, 42:273  
 GABA uptake site, post-mortem brain, 42:273  
 genetics, age of onset, 41:107  
 genetics, attention, 44:125  
 genetics, chromosome 5, 44:171  
 genetics, diagnostic subtypes, 41:107  
 genetics, high-risk study, 44:125  
 genetics, HLA, 41:99  
 genetics, linkage, 41:99  
 genetics, multiplex families, 41:99  
 genetics, reaction time, 44:125  
 genetics, siblings, 41:107  
 glutamate uptake site, basal ganglia, 42:273  
 glutamate uptake site, GABA uptake site, 42:273  
 glutamate uptake site, post-mortem brain, 42:273  
 growth hormone at night, age of onset, 41:155  
 growth hormone, circadian rhythm, 41:155  
 growth hormone, domperidone, 42:159  
 growth hormone, dopamine, 42:159  
 growth hormone, prolactin, 42:159  
 growth hormone, sleep, 41:155  
 haloperidol, abnormal-movement disorders, 41:191  
 haloperidol, dyskinesia, 41:191  
 haloperidol, EEG, 42:129  
 haloperidol, homovanillic acid, 41:191  
 haloperidol, negative symptoms, 41:191  
 haloperidol, prolactin, 41:191  
 haloperidol, pupillometry, 43:287  
 haloperidol, relapse, 43:287  
 haloperidol, side effects, 41:191  
 haloperidol, treatment response, 42:129  
 high-risk study, attention, 44:125  
 high-risk study, genetics, 44:125  
 high-risk study, reaction time, 44:125  
 HLA, genetics, 41:99  
 HLA, linkage, 41:99  
 HLA, multiplex families, 41:99  
 homovanillic acid, abnormal-movement disorders, 41:191  
 homovanillic acid, dyskinesia, 41:191

**Schizophrenia** continued

homovanillic acid, haloperidol, 41:191  
 homovanillic acid, negative symptoms, 41:191  
 homovanillic acid, neuroleptics, 41:191  
 homovanillic acid, prolactin, 41:191  
 homovanillic acid, side effects, 41:191  
 immunology, interleukin-2, 44:113  
 immunology, neopterin, 42:121  
 immunology, symptom severity, 42:121  
 interleukin-2, immunology, 44:113  
 laterality, attention, 43:87  
 laterality, negative symptoms, 43:87  
 laterality, reaction time, 43:87  
 linkage, genetics, 41:99  
 linkage, HLA, 41:99  
 linkage, multiplex families, 41:99  
 MAO inhibitors, deprenyl, 42:189  
 MAO inhibitors, negative symptoms, 42:189  
 MCPP, ACTH, 43:1  
 MCPP, prolactin, 43:1  
 MCPP, serotonin, 43:1  
 MCPP, temperature of body, 43:1  
 MHPG, evoked potentials, 44:21  
 MHPG, norepinephrine, 44:21  
 MHPG, sensory gating, 44:21  
 monoamine oxidase, affective disorder, 44:1  
 monoamine oxidase, cortisol, 44:1  
 mood state assessment, depression, 42:199  
 mood state assessment, self vs. observer ratings, 42:199  
 multiplex families, genetics, 41:99  
 multiplex families, HLA, 41:99  
 multiplex families, linkage, 41:99  
 negative symptoms, abnormal-movement disorders, 41:191  
 negative symptoms, attention, 43:87  
 negative symptoms, computed tomography, 44:55  
 negative symptoms, cortical atrophy, 44:55  
 negative symptoms, deprenyl, 42:189  
 negative symptoms, dyskinesia, 41:191  
 negative symptoms, factor analysis, 44:153  
 negative symptoms, haloperidol, 41:191  
 negative symptoms, homovanillic acid, 41:191  
 negative symptoms, laterality, 43:87  
 negative symptoms, MAO inhibitors, 42:189  
 negative symptoms, neuroleptics, 41:191  
 negative symptoms, outcome, 43:215  
 negative symptoms, prolactin, 41:191  
 negative symptoms, reaction time, 43:87  
 negative symptoms, side effects, 41:191  
 negative symptoms, ventricle-brain ratio, 44:55  
 neopterin, immunology, 42:121  
 neopterin, symptom severity, 42:121

**Schizophrenia** continued

neurodegeneration, enolase, 43:187  
 neuroleptic malignant syndrome, neuroleptics, 44:251  
 neuroleptic malignant syndrome, temperature, 44:251  
 neuroleptics, abnormal-movement disorders, 41:191  
 neuroleptics, bioassay vs. radioimmunoassay, 41:249  
 neuroleptics, ceruleotide, 43:129  
 neuroleptics, clozapine, 41:25  
 neuroleptics, dyskinesia, 41:191  
 neuroleptics, EEG, 42:129  
 neuroleptics, electrodermal activity, 42:145  
 neuroleptics, eye movements, 41:25  
 neuroleptics, homovanillic acid, 41:191  
 neuroleptics, negative symptoms, 41:191  
 neuroleptics, neuroleptic malignant syndrome, 44:251  
 neuroleptics, Parkinsonism, 41:9  
 neuroleptics, positive symptoms, 42:145  
 neuroleptics, prolactin, 41:191, 41:249  
 neuroleptics, pupillometry, 43:287  
 neuroleptics, relapse, 43:287  
 neuroleptics, saccadic intrusions, 41:25  
 neuroleptics, side effects, 41:9, 41:191, 43:129  
 neuroleptics, tardive dyskinesia, 43:129  
 neuroleptics, temperature, 44:251  
 neuroleptics, terguride, 41:9  
 neuroleptics, treatment response, 42:129  
 neuron-specific enolase, CSF, 43:187  
 neuropsychological tests, color naming, 41:137  
 neuropsychological tests, frontal lobe, 41:137  
 neuropsychological tests, rehabilitation, 43:223  
 neuropsychological tests, social skills, 43:223  
 neuropsychological tests, Stroop task, 41:137  
 norepinephrine, evoked potentials, 44:21  
 norepinephrine, MHPG, 44:21  
 norepinephrine, sensory gating, 44:21  
 outcome, negative symptoms, 43:215  
 paranoid subtype, affective disorder, 43:93  
 paranoid subtype, eye movements, 43:93  
 paranoid subtype, saccades, 43:93  
 Parkinsonism, neuroleptics, 41:9  
 Parkinsonism, side effects, 41:9  
 Parkinsonism, terguride, 41:9  
 peptides, cerebrospinal fluid, 43:13  
 peptides, CRH, 43:13  
 peptides, somatostatin, 43:13  
 peptides, TRH, 43:13  
 platelets, delusional state, 41:17

**Schizophrenia** continued

- platelets, dopamine, 41:17
- polysomnography, calcium binding protein, 42:53
- polysomnography, cholinesterase isozymes, 43:23
- polysomnography, chromogranin A, 42:53
- polysomnography, sleep, 42:53, 43:23
- positive symptoms, electrodermal activity, 42:145
- positive symptoms, neuroleptics, 42:145
- post-mortem brain, basal ganglia, 42:273
- post-mortem brain, GABA uptake site, 42:273
- post-mortem brain, glutamate uptake site, 42:273
- post-mortem study, entorhinal cortex, 44:79
- prolactin, abnormal-movement disorders, 41:191
- prolactin, ACTH, 43:1
- prolactin, bioassay vs. radioimmunoassay, 41:249
- prolactin, domperidone, 42:159
- prolactin, dopamine, 42:159
- prolactin, dyskinesia, 41:191
- prolactin, growth hormone, 42:159
- prolactin, haloperidol, 41:191
- prolactin, homovanillic acid, 41:191
- prolactin, MCPP, 43:1
- prolactin, negative symptoms, 41:191
- prolactin, neuroleptics, 41:191, 41:249
- prolactin, serotonin, 43:1
- prolactin, side effects, 41:191
- prolactin, temperature of body, 43:1
- pupillometry, haloperidol, 43:287
- pupillometry, neuroleptics, 43:287
- pupillometry, relapse, 43:287
- reaction time, attention, 43:87, 44:125
- reaction time, genetics, 44:125
- reaction time, high-risk study, 44:125
- reaction time, laterality, 43:87
- reaction time, negative symptoms, 43:87
- rehabilitation, neuropsychological tests, 43:223
- rehabilitation, social skills, 43:223
- relapse, haloperidol, 43:287
- relapse, neuroleptics, 43:287
- relapse prediction, content analysis, 41:275
- relapse prediction, expressed emotion, 41:275
- relapse prediction, family interview, 41:275
- relapse, pupillometry, 43:287
- saccades, affective disorder, 43:93
- saccades, eye movements, 43:93
- saccades, paranoid subtype, 43:93
- saccadic intrusions, clozapine, 41:25
- saccadic intrusions, eye movements, 41:25
- Schizophrenia** continued
- saccadic intrusions, neuroleptics, 41:25
- self vs. observer ratings, depression, 42:199
- self vs. observer ratings, mood state assessment, 42:199
- sensory gating, evoked potentials, 44:21
- sensory gating, MHPG, 44:21
- sensory gating, norepinephrine, 44:21
- serotonin, ACTH, 43:1
- serotonin, MCPP, 43:1
- serotonin, prolactin, 43:1
- serotonin, temperature of body, 43:1
- siblings, age of onset, 41:107
- siblings, diagnostic subtypes, 41:107
- siblings, genetics, 41:107
- side effects, abnormal-movement disorders, 41:191
- side effects, ceruleotide, 43:129
- side effects, dyskinesia, 41:191
- side effects, haloperidol, 41:191
- side effects, homovanillic acid, 41:191
- side effects, negative symptoms, 41:191
- side effects, neuroleptics, 41:9, 41:191, 43:129
- side effects, Parkinsonism, 41:9
- side effects, prolactin, 41:191
- side effects, tardive dyskinesia, 43:129
- side effects, terguride, 41:9
- sleep, calcium binding protein, 42:53
- sleep, cholinesterase isozymes, 43:23
- sleep, chromogranin A, 42:53
- sleep, circadian rhythm, 41:155
- sleep, growth hormone, 41:155
- sleep, polysomnography, 42:53, 43:23
- social skills, neuropsychological tests, 43:223
- social skills, rehabilitation, 43:223
- somatostatin, cerebrospinal fluid, 43:13
- somatostatin, CRH, 43:13
- somatostatin, peptides, 43:13
- somatostatin, TRH, 43:13
- Strooptask, color naming, 41:137
- Strooptask, frontal lobe, 41:137
- subtype diagnosis, computed tomography, 42:209
- subtype diagnosis, symptomatology, 42:209
- subtype diagnosis, ventricular size, 42:209
- symptom response, acute psychosis, 41:147
- symptom severity, emotion, 42:253
- symptom severity, facial affective discrimination, 42:253
- symptom severity, immunology, 42:121
- symptom severity, neopterin, 42:121
- symptomatology, computed tomography, 42:209
- symptomatology, subtype diagnosis, 42:209
- symptomatology, ventricular size, 42:209
- tardive dyskinesia, ceruleotide, 43:129

**Schizophrenia** continued

tardive dyskinesia, neuroleptics, 43:129  
 temperature, neuroleptic malignant syndrome, 44:251  
 temperature, neuroleptics, 44:251  
 temperature of body, ACTH, 43:1  
 temperature of body, MCPP, 43:1  
 temperature of body, prolactin, 43:1  
 temperature of body, serotonin, 43:1  
 terguride, neuroleptics, 41:9  
 terguride, Parkinsonism, 41:9  
 terguride, side effects, 41:9  
 thought disorder, factor analysis, 44:141  
 treatment response, EEG, 42:129  
 treatment response, haloperidol, 42:129  
 treatment response, neuroleptics, 42:129  
 TRH, cerebrospinal fluid, 43:13  
 TRH, CRH, 43:13  
 TRH, peptides, 43:13  
 TRH, somatostatin, 43:13  
 ventricle-brain ratio, computed tomography, 44:55  
 ventricle-brain ratio, cortical atrophy, 44:55  
 ventricle-brain ratio, negative symptoms, 44:55  
 ventricular size, computed tomography, 42:209  
 ventricular size, subtype diagnosis, 42:209  
 ventricular size, symptomatology, 42:209

**Schizotypy**

assortative mating, genetics, 41:283  
 eye movements, hand preference, 41:115  
 eye movements, intelligence, 41:115  
 eye movements, laterality, 41:115  
 eye movements, neuropsychological tests, 41:115  
 eye movements, normal men, 41:115  
 genetics, assortative mating, 41:283  
 hand preference, eye movements, 41:115  
 hand preference, intelligence, 41:115  
 hand preference, laterality, 41:115  
 hand preference, neuropsychological tests, 41:115  
 hand preference, normal men, 41:115  
 intelligence, eye movements, 41:115  
 intelligence, hand preference, 41:115  
 intelligence, laterality, 41:115  
 intelligence, neuropsychological tests, 41:115  
 intelligence, normal men, 41:115  
 laterality, eye movements, 41:115  
 laterality, hand preference, 41:115  
 laterality, intelligence, 41:115  
 laterality, neuropsychological tests, 41:115  
 laterality, normal men, 41:115  
 neuropsychological tests, eye movements, 41:115

**Schizotypy** continued

neuropsychological tests, hand preference, 41:115  
 neuropsychological tests, intelligence, 41:115  
 neuropsychological tests, laterality, 41:115  
 neuropsychological tests, normal men, 41:115  
 normal men, eye movements, 41:115  
 normal men, hand preference, 41:115  
 normal men, intelligence, 41:115  
 normal men, laterality, 41:115  
 normal men, neuropsychological tests, 41:115

**Serotonin**

ACTH, MCPP, 43:1  
 ACTH, prolactin, 43:1  
 ACTH, schizophrenia, 43:1  
 ACTH, temperature of body, 43:1  
 affective disorder, cortisol, 43:65, 43:137  
 affective disorder, desipramine, 43:65  
 affective disorder, fenfluramine, 43:137  
 affective disorder, MCPP, 43:65  
 affective disorder, melancholia, 43:137  
 affective disorder, norepinephrine, 43:65  
 affective disorder, panic disorder, 43:65  
 affective disorder, prolactin, 43:137  
 aggression, childhood disorders, 43:263  
 aggression, cortisol, 43:263  
 aggression, disruptive behavior disorder, 43:263  
 aggression, fenfluramine, 43:263  
 aggression, prolactin, 43:263  
 catecholamines in urine, memory, 43:277  
 catecholamines in urine, MHPG, 43:277  
 catecholamines in urine, neuropsychological tasks, 43:277  
 catecholamines in urine, Tourette's syndrome, 43:277  
 childhood disorders, aggression, 43:263  
 childhood disorders, cortisol, 43:263  
 childhood disorders, disruptive behavior disorder, 43:263  
 childhood disorders, fenfluramine, 43:263  
 childhood disorders, prolactin, 43:263  
 circadian rhythms, cortisol, 43:161  
 circadian rhythms, melatonin, 43:161  
 circadian rhythms, platelet serotonin uptake, 43:161  
 circadian rhythms, prolactin, 43:161  
 cortisol, affective disorder, 43:137  
 cortisol, affective disorder, 43:65  
 cortisol, aggression, 43:263  
 cortisol, childhood disorders, 43:263  
 cortisol, circadian rhythms, 43:161  
 cortisol, desipramine, 43:65  
 cortisol, disruptive behavior disorder, 43:263

**Serotonin** continued

cortisol, fenfluramine, 43:137, 43:263  
 cortisol, MCPP, 43:65  
 cortisol, melancholia, 43:137  
 cortisol, melatonin, 43:161  
 cortisol, norepinephrine, 43:65  
 cortisol, panic disorder, 43:65  
 cortisol, platelet serotonin uptake, 43:161  
 cortisol, prolactin, 43:137, 43:161, 43:263  
 desipramine, affective disorder, 43:65  
 desipramine, cortisol, 43:65  
 desipramine, MCPP, 43:65  
 desipramine, norepinephrine, 43:65  
 desipramine, panic disorder, 43:65  
 disruptive behavior disorder, aggression, 43:263  
 disruptive behavior disorder, childhood disorders, 43:263  
 disruptive behavior disorder, cortisol, 43:263  
 disruptive behavior disorder, fenfluramine, 43:263  
 disruptive behavior disorder, prolactin, 43:263  
 fenfluramine, affective disorder, 43:137  
 fenfluramine, aggression, 43:263  
 fenfluramine, childhood disorders, 43:263  
 fenfluramine, cortisol, 43:137, 43:263  
 fenfluramine, disruptive behavior disorder, 43:263  
 fenfluramine, melancholia, 43:137  
 fenfluramine, obsessive-compulsive disorder, 42:81  
 fenfluramine, prolactin, 42:81, 43:137, 43:263  
 fenfluramine, sex differences, 42:81  
 5-HIAA, indole-3-acetic acid, 41:267  
 5-HIAA, obsessive-compulsive disorder, 41:267  
 5-HIAA, Tourette's syndrome, 41:267  
 5-HIAA, tryptamine, 41:267  
 imipramine, obsessive-compulsive disorder, 42:41  
 imipramine, platelet imipramine binding, 42:41  
 imipramine, sulfotransferase in platelets, 42:41  
 indole-3-acetic acid, 5-HIAA, 41:267  
 indole-3-acetic acid, obsessive-compulsive disorder, 41:267  
 indole-3-acetic acid, Tourette's syndrome, 41:267  
 indole-3-acetic acid, tryptamine, 41:267  
 MCPP, ACTH, 43:1  
 MCPP, affective disorder, 43:65  
 MCPP, cortisol, 43:65

**Serotonin** continued

MCPP, desipramine, 43:65  
 MCPP, norepinephrine, 43:65  
 MCPP, panic disorder, 43:65  
 MCPP, prolactin, 43:1  
 MCPP, schizophrenia, 43:1  
 MCPP, temperature of body, 43:1  
 melancholia, affective disorder, 43:137  
 melancholia, cortisol, 43:137  
 melancholia, fenfluramine, 43:137  
 melancholia, prolactin, 43:137  
 melatonin, circadian rhythms, 43:161  
 melatonin, cortisol, 43:161  
 melatonin, platelet serotonin uptake, 43:161  
 melatonin, prolactin, 43:161  
 memory, catecholamines in urine, 43:277  
 memory, MHPG, 43:277  
 memory, neuropsychological tasks, 43:277  
 memory, Tourette's syndrome, 43:277  
 MHPG, catecholamines in urine, 43:277  
 MHPG, memory, 43:277  
 MHPG, neuropsychological tasks, 43:277  
 MHPG, Tourette's syndrome, 43:277  
 neuropsychological tasks, catecholamines in urine, 43:277  
 neuropsychological tasks, memory, 43:277  
 neuropsychological tasks, MHPG, 43:277  
 neuropsychological tasks, Tourette's syndrome, 43:277  
 norepinephrine, affective disorder, 43:65  
 norepinephrine, cortisol, 43:65  
 norepinephrine, desipramine, 43:65  
 norepinephrine, MCPP, 43:65  
 norepinephrine, panic disorder, 43:65  
 obsessive-compulsive disorder, fenfluramine, 42:81  
 obsessive-compulsive disorder, 5-HIAA, 41:267  
 obsessive-compulsive disorder, imipramine, 42:41  
 obsessive-compulsive disorder, indole-3-acetic acid, 41:267  
 obsessive-compulsive disorder, platelet imipramine binding, 42:41  
 obsessive-compulsive disorder, prolactin, 42:81  
 obsessive-compulsive disorder, sex differences, 42:81  
 obsessive-compulsive disorder, sulfotransferase in platelets, 42:41  
 obsessive-compulsive disorder, Tourette's syndrome, 41:267  
 obsessive-compulsive disorder, tryptamine, 41:267  
 panic disorder, affective disorder, 43:65  
 panic disorder, cortisol, 43:65

**Serotonin** continued

panic disorder, desipramine, 43:65  
 panic disorder, MCPP, 43:65  
 panic disorder, norepinephrine, 43:65  
 platelet imipramine binding, imipramine, 42:41  
 platelet imipramine binding, obsessive-compulsive disorder, 42:41  
 platelet imipramine binding, sulfotransferase in platelets, 42:41  
 platelet serotonin uptake, circadian rhythms, 43:161  
 platelet serotonin uptake, cortisol, 43:161  
 platelet serotonin uptake, melatonin, 43:161  
 platelet serotonin uptake, prolactin, 43:161  
 prolactin, ACTH, 43:1  
 prolactin, affective disorder, 43:137  
 prolactin, aggression, 43:263  
 prolactin, childhood disorders, 43:263  
 prolactin, circadian rhythms, 43:161  
 prolactin, cortisol, 43:137, 43:161, 43:263  
 prolactin, disruptive behavior disorder, 43:263  
 prolactin, fenfluramine, 42:81, 43:137, 43:263  
 prolactin, MCPP, 43:1  
 prolactin, melancholia, 43:137  
 prolactin, melatonin, 43:161  
 prolactin, obsessive-compulsive disorder, 42:81  
 prolactin, platelet serotonin uptake, 43:161  
 prolactin, schizophrenia, 43:1  
 prolactin, sex differences, 42:81  
 prolactin, temperature of body, 43:1  
 schizophrenia, ACTH, 43:1  
 schizophrenia, MCPP, 43:1  
 schizophrenia, prolactin, 43:1  
 schizophrenia, temperature of body, 43:1  
 sex differences, fenfluramine, 42:81  
 sex differences, obsessive-compulsive disorder, 42:81  
 sex differences, prolactin, 42:81  
 sulfotransferase in platelets, imipramine, 42:41  
 sulfotransferase in platelets, obsessive-compulsive disorder, 42:41  
 sulfotransferase in platelets, platelet imipramine binding, 42:41  
 temperature of body, ACTH, 43:1  
 temperature of body, MCPP, 43:1  
 temperature of body, prolactin, 43:1  
 temperature of body, schizophrenia, 43:1  
 Tourette's syndrome, catecholamines in urine, 43:277  
 Tourette's syndrome, 5-HIAA, 41:267  
 Tourette's syndrome, indole-3-acetic acid, 41:267  
 Tourette's syndrome, memory, 43:277

**Serotonin** continued

Tourette's syndrome, MHPG, 43:277  
 Tourette's syndrome, neuropsychological tasks, 43:277  
 Tourette's syndrome, obsessive-compulsive disorder, 41:267  
 Tourette's syndrome, tryptamine, 41:267  
 tryptamine, 5-HIAA, 41:267  
 tryptamine, indole-3-acetic acid, 41:267  
 tryptamine, obsessive-compulsive disorder, 41:267  
 tryptamine, Tourette's syndrome, 41:267  
**Sleep**  
 adolescent depression, affective disorder, 41:53  
 adolescent depression, childhood depression, 41:53  
 adolescent depression, family studies, 41:53  
 adolescent depression, polysomnography, 41:53  
 affective disorder, adolescent depression, 41:53  
 affective disorder, agoraphobia, 44:41  
 affective disorder, childhood depression, 41:53  
 affective disorder, delta EEG, 41:65  
 affective disorder, family studies, 41:53  
 affective disorder, longitudinal studies, 42:27  
 affective disorder, panic disorder, 44:41  
 affective disorder, polysomnography, 41:53, 41:65, 42:13, 42:27, 44:41  
 affective disorder, psychotherapy, 42:13, 42:27  
 affective disorder, remission, 42:27  
 affective disorder, treatment response, 42:13  
 agoraphobia, affective disorder, 44:41  
 agoraphobia, panic disorder, 44:41  
 agoraphobia, polysomnography, 44:41  
 bereavement, depressed mood, 43:43  
 bereavement, polysomnography, 43:43  
 calcium binding protein, chromogranin A, 42:53  
 calcium binding protein, polysomnography, 42:53  
 calcium binding protein, schizophrenia, 42:53  
 childhood depression, adolescent depression, 41:53  
 childhood depression, affective disorder, 41:53  
 childhood depression, family studies, 41:53  
 childhood depression, polysomnography, 41:53  
 cholinesterase isozymes, polysomnography, 43:23  
 cholinesterase isozymes, schizophrenia, 43:23

**Sleep** continued

chromogranin A, calcium binding protein, 42:53  
 chromogranin A, polysomnography, 42:53  
 chromogranin A, schizophrenia, 42:53  
 circadian rhythm, growth hormone, 41:155  
 circadian rhythm, schizophrenia, 41:155  
 delta EEG, affective disorder, 41:65  
 delta EEG, polysomnography, 41:65  
 depressed mood, bereavement, 43:43  
 depressed mood, polysomnography, 43:43  
 family studies, adolescent depression, 41:53  
 family studies, affective disorder, 41:53  
 family studies, childhood depression, 41:53  
 family studies, polysomnography, 41:53  
 growth hormone, circadian rhythm, 41:155  
 growth hormone, schizophrenia, 41:155  
 longitudinal studies, affective disorder, 42:27  
 longitudinal studies, polysomnography, 42:27  
 longitudinal studies, psychotherapy, 42:27  
 longitudinal studies, remission, 42:27  
 panic disorder, affective disorder, 44:41  
 panic disorder, agoraphobia, 44:41  
 panic disorder, polysomnography, 44:41  
 polysomnography, adolescent depression, 41:53  
 polysomnography, affective disorder, 41:53, 41:65, 42:13, 42:27, 44:41  
 polysomnography, agoraphobia, 44:41  
 polysomnography, bereavement, 43:43  
 polysomnography, calcium binding protein, 42:53  
 polysomnography, childhood depression, 41:53  
 polysomnography, cholinesterase isozymes, 43:23  
 polysomnography, chromogranin A, 42:53  
 polysomnography, delta EEG, 41:65  
 polysomnography, depressed mood, 43:43  
 polysomnography, family studies, 41:53  
 polysomnography, longitudinal studies, 42:27  
 polysomnography, panic disorder, 44:41  
 polysomnography, psychotherapy, 42:13, 42:27  
 polysomnography, remission, 42:27  
 polysomnography, schizophrenia, 42:53, 43:23  
 polysomnography, treatment response, 42:13  
 psychotherapy, affective disorder, 42:13, 42:27  
 psychotherapy, longitudinal studies, 42:27  
 psychotherapy, polysomnography, 42:13, 42:27  
 psychotherapy, remission, 42:27  
 psychotherapy, treatment response, 42:13  
 remission, affective disorder, 42:27  
 remission, longitudinal studies, 42:27  
 remission, polysomnography, 42:27

**Sleep** continued

remission, psychotherapy, 42:27  
 schizophrenia, calcium binding protein, 42:53  
 schizophrenia, cholinesterase isozymes, 43:23  
 schizophrenia, chromogranin A, 42:53  
 schizophrenia, circadian rhythm, 41:155  
 schizophrenia, growth hormone, 41:155  
 schizophrenia, polysomnography, 42:53, 43:23  
 treatment response, affective disorder, 42:13  
 treatment response, polysomnography, 42:13  
 treatment response, psychotherapy, 42:13  
**Stroop task**  
 color naming, frontal lobe, 41:137  
 color naming, neuropsychological tests, 41:137  
 color naming, schizophrenia, 41:137  
 frontal lobe, color naming, 41:137  
 frontal lobe, neuropsychological tests, 41:137  
 frontal lobe, schizophrenia, 41:137  
 neuropsychological tests, color naming, 41:137  
 neuropsychological tests, frontal lobe, 41:137  
 neuropsychological tests, schizophrenia, 41:137  
 schizophrenia, color naming, 41:137  
 schizophrenia, frontal lobe, 41:137  
 schizophrenia, neuropsychological tests, 41:137  
**Substance abuse**  
 abstinence, carbidopa treatment, 43:77  
 abstinence, cocaine, 43:77  
 abstinence, growth hormone, 43:77  
 abstinence, homovanillic acid, 43:77  
 abstinence, MHPG, 43:77  
 abstinence, prolactin, 43:77  
 carbidopa treatment, abstinence, 43:77  
 carbidopa treatment, cocaine, 43:77  
 carbidopa treatment, growth hormone, 43:77  
 carbidopa treatment, homovanillic acid, 43:77  
 carbidopa treatment, MHPG, 43:77  
 carbidopa treatment, prolactin, 43:77  
 cocaine, abstinence, 43:77  
 cocaine, carbidopa treatment, 43:77  
 cocaine, growth hormone, 43:77  
 cocaine, homovanillic acid, 43:77  
 cocaine, MHPG, 43:77  
 cocaine, prolactin, 43:77  
 growth hormone, abstinence, 43:77  
 growth hormone, carbidopa treatment, 43:77  
 growth hormone, cocaine, 43:77  
 growth hormone, homovanillic acid, 43:77  
 growth hormone, MHPG, 43:77  
 growth hormone, prolactin, 43:77  
 HIV, neuropsychological tests, 41:163  
 homovanillic acid, abstinence, 43:77  
 homovanillic acid, carbidopa treatment, 43:77  
 homovanillic acid, cocaine, 43:77

**Substance abuse** continued  
 homovanillic acid, growth hormone, 43:77  
 homovanillic acid, MHPG, 43:77  
 homovanillic acid, prolactin, 43:77  
 MHPG, abstinence, 43:77  
 MHPG, carbidopa treatment, 43:77  
 MHPG, cocaine, 43:77  
 MHPG, growth hormone, 43:77  
 MHPG, homovanillic acid, 43:77  
 MHPG, prolactin, 43:77  
 neuropsychological tests, HIV, 41:163  
 prolactin, abstinence, 43:77  
 prolactin, carbidopa treatment, 43:77  
 prolactin, cocaine, 43:77  
 prolactin, growth hormone, 43:77  
 prolactin, homovanillic acid, 43:77  
 prolactin, MHPG, 43:77

**Symptom Checklist-90**  
 obsessive-compulsive disorder, reliability and validity, 41:37  
 reliability and validity, obsessive-compulsive disorder, 41:37

**Terguride**  
 neuroleptics, Parkinsonism, 41:9  
 neuroleptics, schizophrenia, 41:9  
 neuroleptics, side effects, 41:9  
 Parkinsonism, neuroleptics, 41:9  
 Parkinsonism, schizophrenia, 41:9  
 schizophrenia, neuroleptics, 41:9  
 schizophrenia, Parkinsonism, 41:9  
 schizophrenia, side effects, 41:9  
 side effects, neuroleptics, 41:9  
 side effects, schizophrenia, 41:9

**Tourette's syndrome**  
 catecholamines in urine, memory, 43:277  
 catecholamines in urine, MHPG, 43:277  
 catecholamines in urine, neuropsychological tasks, 43:277  
 catecholamines in urine, serotonin, 43:277  
 5-HIAA, indole-3-acetic acid, 41:267  
 5-HIAA, obsessive-compulsive disorder, 41:267  
 5-HIAA, serotonin, 41:267  
 5-HIAA, tryptamine, 41:267  
 homovanillic acid, neuropsychological tasks, 43:277  
 homovanillic acid, trace amines, 43:277  
 indole-3-acetic acid, 5-HIAA, 41:267  
 indole-3-acetic acid, obsessive-compulsive disorder, 41:267  
 indole-3-acetic acid, serotonin, 41:267  
 indole-3-acetic acid, tryptamine, 41:267  
 memory, catecholamines in urine, 43:277  
 memory, MHPG, 43:277  
 memory, neuropsychological tasks, 43:277

**Tourette's syndrome** continued  
 memory, serotonin, 43:277  
 MHPG, catecholamines in urine, 43:277  
 MHPG, memory, 43:277  
 MHPG, neuropsychological tasks, 43:277  
 MHPG, serotonin, 43:277  
 neuropsychological tasks, catecholamines in urine, 43:277  
 neuropsychological tasks, homovanillic acid, 43:277  
 neuropsychological tasks, memory, 43:277  
 neuropsychological tasks, MHPG, 43:277  
 neuropsychological tasks, serotonin, 43:277  
 neuropsychological tasks, trace amines, 43:277  
 obsessive-compulsive disorder, 5-HIAA, 41:267  
 obsessive-compulsive disorder, indole-3-acetic acid, 41:267  
 obsessive-compulsive disorder, serotonin, 41:267  
 obsessive-compulsive disorder, tryptamine, 41:267  
 serotonin, catecholamines in urine, 43:277  
 serotonin, 5-HIAA, 41:267  
 serotonin, indole-3-acetic acid, 41:267  
 serotonin, memory, 43:277  
 serotonin, MHPG, 43:277  
 serotonin, neuropsychological tasks, 43:277  
 serotonin, obsessive-compulsive disorder, 41:267  
 serotonin, tryptamine, 41:267  
 trace amines, homovanillic acid, 43:277  
 trace amines, neuropsychological tasks, 43:277  
 tryptamine, 5-HIAA, 41:267  
 tryptamine, indole-3-acetic acid, 41:267  
 tryptamine, obsessive-compulsive disorder, 41:267  
 tryptamine, serotonin, 41:267

**Tridimensional Personality Questionnaire**  
 affective disorder, manic symptoms, 41:215  
 affective disorder, psychotic symptoms, 41:215  
 manic symptoms, affective disorder, 41:215  
 manic symptoms, psychotic symptoms, 41:215  
 psychotic symptoms, affective disorder, 41:215

**Tryptophan**  
 psychotic symptoms, manic symptoms, 41:215  
 5-HIAA, indole-3-acetic acid, 41:267  
 5-HIAA, obsessive-compulsive disorder, 41:267  
 5-HIAA, serotonin, 41:267  
 5-HIAA, Tourette's syndrome, 41:267  
 indole-3-acetic acid, 5-HIAA, 41:267  
 indole-3-acetic acid, obsessive-compulsive disorder, 41:267

**Tryptophan** continued

indole-3-acetic acid, serotonin, 41:267  
indole-3-acetic acid, Tourette's syndrome, 41:267  
obsessive-compulsive disorder, 5-HIAA, 41:267  
obsessive-compulsive disorder, indole-3-acetic acid, 41:267  
obsessive-compulsive disorder, serotonin, 41:267  
obsessive-compulsive disorder, Tourette's syndrome, 41:267  
serotonin, 5-HIAA, 41:267  
serotonin, indole-3-acetic acid, 41:267  
serotonin, obsessive-compulsive disorder, 41:267  
serotonin, Tourette's syndrome, 41:267  
Tourette's syndrome, 5-HIAA, 41:267  
Tourette's syndrome, indole-3-acetic acid, 41:267

**Tryptophan** continued

Tourette's syndrome, obsessive-compulsive disorder, 41:267  
Tourette's syndrome, serotonin, 41:267  
**Vagal tone**  
diazepam, heart rate, 41:89  
diazepam, norepinephrine, 41:89  
diazepam, normal men, 41:89  
heart rate, diazepam, 41:89  
heart rate, norepinephrine, 41:89  
heart rate, normal men, 41:89  
norepinephrine, diazepam, 41:89  
norepinephrine, heart rate, 41:89  
norepinephrine, normal men, 41:89  
normal men, diazepam, 41:89  
normal men, heart rate, 41:89  
normal men, norepinephrine, 41:89